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Délivrance in vivo de siRNA et évaluation de leur effet 
antiviral contre le virus de la peste des petits ruminants 
(PPRV) 
 
RESUME EN FRANCAIS 
 
par 
 
NIZAMANI Zaheer Ahmed 
 
 
La peste des petits ruminants (PPR) est une maladie virale contagieuse des chèvres, des 
moutons et de certains ruminants sauvages. Elle induit une maladie systémique sévère avec 
fièvre, dégradation de l’état général, troubles respiratoires et digestifs et aboutit très souvent à 
la mort de l’animal. La maladie est due à un morbillivirus de la famille des Paramyxoviridae. 
Les morbillivirus infectent de nombreuses espèces, l’homme par le virus de la rougeole les 
ruminants par les virus de la peste bovine et de la peste de petits ruminants, les carnivores par 
le virus de la maladie de Carré et les mammifères marins. Il s’agit de virus enveloppés 
pléiomorphes à ARN simple brin de polarité négative. Le virus est constitué de six protéines 
structurales, la nucléoprotéine étant la plus représentée.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1 : Représentation schématique du Morbillivirus (d’après Moss et al., 2006 [1]). 
 
Après pénétration dans l’organisme, le virus PPR infecte en premier lieu les cellules du 
système lymphoïde, puis une seconde phase de réplication au niveau des cellules épithéliales 
permet au virus d’être ré-excrété. Bien que peu résistant dans le milieu extérieur, le virus se 
transmet toutefois de façon efficace à la faveur de contacts directs entre animaux infectés et 
animaux sensibles. 
Nucléoprotéine 
Protéine de 
Matrice
Polymerase L 
Phosphoprotéine 
Protéine de Fusion  ARN 
Hémagglutinine 
Protéine 
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Décrite pour la première fois en 1942 en Afrique de l’ouest, la maladie est désormais 
reconnue en Afrique, au Moyen-Orient et en Asie (Fig. 2). En Afrique, elle a longtemps été 
cantonnée à l’Afrique subsaharienne. Cependant, dans les cinq dernières années, elle a eu 
tendance à s’étendre vers le Maghreb (Maroc, 2008) et vers l’Afrique du Sud (Tanzanie, 
2009). 
 
Figure 2: Distribution géographique des lignées phylogénétiques du virus de la PPR. 
 
Parmi les moyens de lutte disponible, il y a un vaccin très efficace, permettant en une seule 
injection d’immuniser l’animal sur au moins 3 ans. Toutefois, ce vaccin est en pratique peu 
utilisé dans les zones où la maladie sévit de façon enzootique. La vaccination est 
pratiquement toujours mise en œuvre en situation d’urgence, lorsque l’incidence clinique est 
déjà très marquée. Le contrôle de la maladie est alors plus complexe, plus long et plus 
couteux. La possibilité de combiner une thérapie antivirale avec la vaccination pourrait, le cas 
échéant, permettre d’accélérer le contrôle de la maladie. 
 
Parmi les différentes stratégies thérapeutiques antivirales, il en est une qui suscite 
actuellement et depuis dix ans, des recherches actives. Il s’agit de l’interférence ARN. 
L’interférence ARN est un mécanisme naturel des cellules eucaryotes qui permet la régulation 
de l’expression de gènes, qu’ils soient du soi ou du non soi (d’origine virale). Elle est basée 
sur l’interaction d’un simple brin d’ARN d’une vingtaine de nucléotides (small interfering 
RNA, siRNA) avec un ARN messager présentant la séquence complémentaire du siRNA. 
Cette interaction médiée par un complexe protéique appelé RISC pour RNA « induced 
silencing complex » permet la dégradation spécifique de l’ARNm cible. Cette régulation post-
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transcriptionnelle est parfois si spécifique de la séquence cible qu’une seule mutation dans le 
siRNA peut annuler l’effet. Toutefois, toute mutation n’implique pas forcément une perte 
d’activité. Cela dépend pour l’essentiel de la position de la mutation dans le siRNA, certaines 
positions étant critiques pour l’effet interférent. Par ailleurs, une interaction partielle entre un 
siRNA et un autre ARNm distinct de sa cible est toujours possible et peut aboutir à une 
dérégulation de l’expression d’une protéine importante avec des conséquences négatives. 
Tous ces éléments permettent d’expliquer les contraintes liées à l’utilisation de l’interférence 
ARN en thérapie antivirale :  
 
- le risque d’échappement du virus aux siRNA par simple mutation, soit dans le site de 
reconnaissance, soit à distance de ce site mais à un endroit qui entraîne un changement 
de conformation de l’ARNm rendant le site inaccessible ; 
- le risque d’effets indésirables par interférence ARN sur des ARNm non ciblés ; 
- le risque d’effets secondaires liés à la compétition des siRNA thérapeutiques avec les 
siRNA endogènes ayant un rôle dans la régulation du métabolisme cellulaire 
 
A ces contraintes, s’ajoute la difficulté de délivrer efficacement les siRNA dans le cytoplasme 
cellulaire, près du noyau où se localise le complexe protéique responsable de l’interférence 
ARN. In vitro, la délivrance est assez aisée avec des agents de transfection basés sur des 
liposomes, des peptides ou des vecteurs viraux. In vivo, la mise en œuvre des mêmes systèmes 
de délivrance aboutit le plus souvent à une perte d’efficacité. Différentes raisons peuvent 
expliquer cet écart. L’exposition des siRNA aux enzymes circulantes dont les RNases, est une 
première cause de dégradation rapide des molécules actives, avant même qu’elles n’aient la 
capacité d’entrer dans le cytoplasme des cellules qu’elles sont censées traiter. Les vecteurs 
viraux peuvent avoir des limites dans le ciblage des cellules et par ailleurs, ils posent des 
questions sur le plan de leur innocuité par rapport à leur capacité réplicative le cas échéant ou 
parce qu’ils ont une phase nucléaire dans l’expression des siRNA. 
 
Tout ceci illustre le challenge auquel sont confrontés les chercheurs pour que les ARN 
interférents parviennent jusqu’à exploitation thérapeutique. Seuls quelques uns d’entre eux, 
délivrés localement au niveau des muqueuses, ont été jusqu’à des essais en phase clinique. 
 
Le CIRAD a engagé des travaux sur l’interférence ARN en 2004. Le premier objectif 
consistait à identifier des siRNA actifs in vitro sur plusieurs morbillivirus. Le gène codant la 
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nucléoprotéine (N) virale a été initialement choisie car les outils de détection de ce gène ou de 
son produit étaient disponibles (sondes, anticorps monoclonaux, etc.). Des régions conservées 
de ce gène ont été identifiées et soumises à sélection de séquences siRNA actives par un 
logiciel commercial ou selon des critères extraits de la littérature. Aucun siRNA ciblant une 
région suffisamment conservée du gène N pour être actif sur plusieurs morbillivirus n’a pu 
être identifié. En revanche, trois sites ont été identifiés qui peuvent être efficacement ciblés in 
vitro par des siRNA spécifiques de trois morbillivirus différents, délivrés soit par transfection 
soit par un adénovirus recombinant exprimant des ARN interférents. La stratégie actuelle du 
laboratoire consiste à explorer la capacité d’échappement des morbillivirus au contrôle des 
siRNA et à traiter la question de la délivrance in vivo des siRNA. Le premier volet est l’objet 
d’un autre travail de thèse alors que le second volet est au cœur de ce mémoire. 
 
Pour délivrer un siRNA actif contre le virus de la PPR, notre travail a commencé par la 
production et l’évaluation in vivo de deux systèmes de délivrance, d’une part, des liposomes 
et d’autre part, un adénovirus recombinant exprimant des siRNA. L’adénovirus que nous 
avons choisi était le même que ceux utilisés par des groupes chinois ayant réussi à interférer 
avec la réplication de virus porcins dans l’espèce cible. Nous avons donc décidé d’adopter un 
protocole très similaire, adapté à la chèvre. Toutefois, ni les liposomes, ni l’adénovirus ne se 
sont révélés suffisamment efficaces. Face à ce résultat plutôt décevant, nous avons décidé 
d’explorer d’autres systèmes de délivrance et en parallèle de développer un modèle petit 
animal permettant d’évaluer in vivo et comparativement, les différents systèmes de délivrance 
de siRNA. Deux systèmes alternatifs de délivrance ont été développés puis évalués in vitro. 
Le premier d’entre eux est un peptide capable de pénétrer la membrane cellulaire. Le second 
est un vecteur baculovirus adapté à l’expression en cellules de mammifères. Ces deux 
systèmes ont été évalués in vitro en comparaison avec l’adénovirus précédemment développé, 
dans l’attente de les tester in vivo. Dans le but de comparer quantitativement des effets 
interférents chez l’animal tout en limitant le nombre d’animaux utilisés pour des raisons 
éthiques et en réduisant les coûts, nous avons opté pour le développement d’un modèle souris 
avec évaluation de l’interférence ARN par imagerie in vivo. 
 
1. Evaluation de deux systèmes de délivrance de siRNA chez la chèvre 
Différentes formulations de liposomes basées sur un mélange de liposome cationique 1,2-
dioleoyl-3-trimethylammonium-propane-chloride (DOTAP), de lipide neutre 1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine (DOPE) et de la cardiolipine anionique ont été préparées. 
Ces préparations ont ensuite été intimement mixées avec le siRNA en phase acqueuse pour 
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former des complexes incorporant le siRNA. Un adénovirus recombinant exprimant un court 
ARN en forme de tête d’épingle à cheveux (short hairpin RNA ou shRNA) avait été produit 
en utilisant un kit commercial, juste avant que ne commence ce travail de thèse. 
 
Les lipocomplexes ont été mis au contact des cellules pendant cinq heures, avec une 
concentration finale de siRNA équivalente à 100 nM. D’autres cellules ont été transduites 
avec l’adénovirus recombinant à une multiplicité d’infection de 80. Vingt quatre heures après 
contact avec les lipocomplexes ou 72 heures après transduction par l’adénovirus, les cellules 
ont été infectées avec le virus PPR à une multiplicité d’infection de 0,1 dose cytopathique 
infectieuse 50% (DCI50) par cellule. 
 
L’interférence virale a été mesurée sur le développement de l’effet cytopathique produit par le 
virus PPR ou par quantification de la nucléoprotéine virale par cytométrie en flux. Le contrôle 
positif correspondait à un ARN interférent transfecté par la  Lipofectamine™ 2000 
(Invitrogen)  et le contrôle négatif était un ARN interférant sans rapport avec le virus PPR. 
Une formulation lipidique utilisée avec un rapport de concentrations de 5 pour 1 siRNA s’est 
révélée efficace pour neutraliser 80% de l’effet cytopathique dû au virus PPR. Cet effet était 
comparable à celui obtenu avec la Lipofectamine™ 2000. En revanche, la formulation que 
nous avons sélectionnée conservait un effet inhibiteur à 45% en présence de 60% de sérum de 
chèvre, ce qui se rapproche de l’environnement normal dans lequel le siRNA devra évoluer 
une fois administré à l’animal. Le bas coût de production de cette formulation permet aussi 
son application à grande échelle. La Lipofectamine™ 2000 ou d’autres liposomes disponibles 
dans le commerce seraient efficaces en présence de fortes concentrations de sérum comme 
indiqués par leurs fournisseurs. Cependant, le coût astronomique de leur administration chez 
la chèvre ne permettait pas d’envisager cette solution. L’adénovirus pour sa part, a inhibé 
l’effet cytopathique viral à environ 95% et il n’est pas sensible à la présence de sérum dans le 
milieu. La meilleure formulation lipidique et l’adénovirus ont donc été utilisés chez la chèvre 
pour tenter d’inhiber la réplication du virus PPR. 
 
Trente chèvres ont été réparties en trois groupes. Un premier groupe a reçu l’adénovirus 
recombinant exprimant le siRNA d’intérêt (rAd_NPPRV1shRNA) à la dose de 0,5x1010 DCI50 
par voie intraveineuse. Un second groupe a reçu la même dose d’un adénovirus du commerce 
exprimant un siRNA sans rapport avec le virus PPR (rAd_SCRshRNA). Enfin, le troisième 
groupe a reçu trois administrations consécutives à 24 heures d’intervalle de 12 mg de siRNA 
incorporés dans des lipoplexes. Tous les animaux ont été éprouvés avec une souche virulente 
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de virus PPR, 48 heures après la première administration des antiviraux. L’examen quotidien 
des animaux selon une grille de scores cliniques a permis de quantifier le développement de la 
maladie lorsqu’est présente. Les différences observées, en faveur de la formulation lipidique, 
n’ont pas été significatives au plan statistique. Ceci souligne la difficulté de délivrer 
correctement des siRNA dans les cellules cibles chez l’animal. 
 
 
 
Figure 3 : Evolution des écoulements oculaires et nasaux, stomatite, diarrhée et températures 
après infection PPR dans les groupes de chèvres traitées avec liposome+siRNA NPPRV, 
rAd_NPPRV1shRNA et rAd_SCRshRNA. 
 
Ces premiers résultats insuffisants nous ont amenés à travailler dans deux directions parallèles 
mais complémentaires. Nous avons cherché d’une part, à développer d’autres systèmes de 
délivrances plus performantes et d’autre part, à mettre au point un modèle d’évaluation 
comparative des différents systèmes de délivrance chez la souris, plus compatible avec les 
exigences éthiques en matière d’expérimentation animale. 
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2. Evaluation in vitro de deux nouveaux systèmes de délivrance 
Au cours de la thèse, une collaboration nouée avec un groupe allemand (Institut Friedrich 
Loeffer) et un autre groupe suédois (Université de Stockholm) a permis d’obtenir deux 
nouveaux systèmes de délivrance de siRNA à potentiel in vivo. Le premier est un baculovirus 
BacMam adapté à l’expression en cellules de mammifères et dans lequel le groupe allemand a 
inséré la même cassette d’expression de shRNA que nous avions clonée dans l’adénovirus 
(rBac_NPPRV1shRNA). La représentation schématique de ce nouveau vecteur en comparaison 
avec l’adénovirus est reproduite en Figure 4. Nous avons également obtenu du même groupe 
un baculovirus exprimant un autre shRNA sans rapport avec la PPR (shRNA contre la 
protéine eGFP). 
 
Figure 4 : Représentation schématique des constructions de vecteurs viraux. 
 
Deux peptides nommés PF6 et PF14 nous ont été fournis par le groupe suédois pour une 
évaluation in vitro. Ces molécules, définies comme CPPs (pour cell penetrating peptides) 
modifiées chimiquement, sont capables de former des complexes stables non-covalents avec 
le siRNA et de délivrer efficacement dans l’intérieur de la cellule. Ces peptides avaient les 
séquences suivantes: 
Pol III terminatorshRNA NPPRV1u6 Promoter 
Sense: 5'-GGAUCAACUGGUUUGAGAAtt-3'; Antisense: 3'-ttCCUAGUUGACCAAACUCUU-5' 
Antisense SequenceLoop SequenceSense Sequence Linker 
Top Strand    
5'-CACCGGATCAACTGGTTTGAGAACGAATTCTCAAACCAGTTGATCC-3' 
Bottom Strand  
5'-AAAAGGATCAACTGGTTTGAGAATTCGTTCTCAAACCAGTTGATCC-3' 
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               Sequences peptidiques  
PepFect 6 Stearyl-AGYLLGK[KK2sa4qn4]INLKALAALAKKIL-NH2 
PepFect 14 Stearyl-LLOOLAAAALOOLL -NH2 
 
Les peptides sont complexés avec le siRNA à température ambiante pendant une heure, des 
ratio siRNA/peptide de 1/5 à 1/15 ont été évalués. 
 
Les deux vecteurs viraux et les peptides ont été comparés in vitro à différentes doses avec 
l’agent de transfection classique Lipofectamine™ 2000  pour délivrer le même siRNA contre 
le virus PPR. Une première comparaison entre les deux vecteurs viraux a montré une 
meilleure efficacité in vitro du baculovirus aux fortes concentrations (Fig. 5). L’adénovirus a 
au maximum entraîné une réduction de la progénie virale de 0,7 Log DCI50, alors que le 
baculovirus atteignait 2,2 Log DCI50 et la Lipofectamine™ 2000  3 à 4 Log DCI50.  
 
 
Figure 5 : Inhibition de la production du virus PPR par l’adénovirus ou le baculovirus 
recombinant exprimant le shRNA NPPRV1 (rBac_NPPRV1shRNA). Le titrage du virus PPR a 
été effectué 96 heures après infection à MOI 0,01. 
 
Les deux peptides se sont avérés efficaces dans la délivrance de siRNA in vitro. Le PF6 a été 
le plus efficace, permettant d’inhiber l’expression de la nucléoprotéine virale jusqu’à 99% 
comparativement à 74% avec la lipofectamine (Fig. 6). Cependant, le PF14 a été le plus 
résistant à l’effet délétère de sérum de fœtus de bovin jusqu’à concentration de 30%. 
L’addition de ce sérum en forte concentration avait pour objectif de tester la résistance des 
peptides en milieu riche en sérum comme ce sera le cas lorsqu’ils seront délivrés in vivo. 
1,0E+05
1,6E+05
3,2E+05
5,0E+056,3E+05
3,2E+03
4,0E+04
1,0E+05
1,6E+05
4,0E+05
1,0E+02
1,0E+03
1,0E+04
1,0E+05
1,0E+06
PPRV 25 50 100 200
MOIs
C
C
ID
50
/m
l
rAd_NPPRV1_shRNA rBac_NPPRV1_shRNA
 19  
Toutefois, même si le PF6 a une activité fortement réduite par le sérum, à la concentration de 
30% dans le milieu de culture, il reste encore plus efficace que le PF14. Les résultats de cette 
étude ont montré que le baculovirus recombinant et les peptides PF6 et PF14 pouvait 
présenter un intérêt dans la délivrance siRNA. Il serait alors intéressant de les évaluer in vivo, 
sur un modèle souris. 
 
 
 
 
Figure 6 : Effet de différentes concentrations de siRNA complexées avec le PF6 (graphe du 
haut) et impact de la présence de sérum de fœtus de bovin dans les cultures sur l’efficacité du 
PF6 (graphe du bas). 
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3. Contribution au développement d’un modèle petit animal pour l’évaluation in 
vivo de systèmes de délivrance de siRNA 
Face à la difficulté de passer des études in vitro à l’évaluation in vivo des siRNA dans 
l’espèce cible qui concerne ce travail (les petits ruminants, voir section 1), nous avons 
envisagé la possibilité de développer un modèle souris pour comparer différents systèmes de 
délivrance. Toutefois, les souris classiques de laboratoire ne sont pas sensibles au virus de la 
PPR. Des souris délétées du gène exprimant le récepteur aux interférons de type I se sont 
révélées sensibles à l’infection par le virus de la fièvre catarrhale ovine due à un orbivirus. 
Cependant, quand nous avons testés ces souris avec le virus PPR, aucune infection n’a pu être 
mise en évidence par voie intra-péritonéale. Avec un autre morbillivirus, le virus de la 
rougeole, une équipe INSERM de Lyon a pu développer un modèle d’infection sur des souris 
exprimant le récepteur du virus de la rougeole, croisées avec des souris délétées du gène 
exprimant le récepteur aux interférons de type I. Le laboratoire a donc programmé de tester 
ces souris avec le virus de la PPR et le cas échéant de préparer une lignée de souris 
transgénique exprimant le récepteur du virus PPR. Toutefois, les délais pour aboutir n’étaient 
pas compatibles avec la durée de cette thèse. Aussi, un modèle intermédiaire a été défini. Il 
s’agissait de préparer un système d’expression basé sur un ARNm comprenant la séquence 
cible du siRNA_NPPRV1 et un gène rapporteur. Ce système d’expression doit être inhibé par 
le siRNA in vitro. Puis il sera injecté chez l’animal et on tentera alors d’inhiber ce système 
par la délivrance in vivo du siRNA. Afin de réduire le nombre d’animaux utilisé pour ce 
travail, nous avons choisi d’utiliser l’imagerie in vivo qui permet de suivre de façon cinétique 
chez le même animal l’effet interférent. Les gènes rapporteurs utilisables en imagerie in vivo 
sont les gènes codant pour des enzymes de luminescence, car elles permettent de mesurer un 
signal dans la profondeur des tissus. 
 
Une première construction a été faite avec la séquence siRNA_NPPRV1 placée en amont du 
gène de la Firefly luciférase (Fig. 7). Cette construction a été validée in vitro, dans le sens où 
le siRNA_NPPRV1 a été capable d’éteindre la luminescence de la Firefly (Tab. 1). Pour 
passer cette construction in vivo, il nous a fallu identifier un site d’expression périphérique, 
circonscrit mais accessible aux siRNA par le sang périphérique. Notre choix s’est porté sur 
une injection intramusculaire dans le muscle tibial antérieur. Après avoir validé le principe 
dans un essai réduit sur souris, nous avons engagé un essai pour tester la délivrance de nos 
siRNA avec une préparation à base de liposomes fournie par une entreprise privée avec 
laquelle nous avons noué un partenariat. Cette entreprise avait démontré précédemment dans 
un autre modèle l’efficacité de son système de délivrance de siRNA chez la souris. 
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Cependant, cet essai n’a pas permis de mettre en évidence un effet interférent, principalement 
à cause d’une hétérogénéité d’expression importante d’un membre à l’autre d’un même 
animal et entre animaux. Jusqu’à 30-40% des souris peuvent ne pas répondre à l’injection 
dans le muscle tibialis. Et pour celles qui répondent, le niveau d’expression peut varier dans 
des proportions importantes. Cette hétérogénéité est propre à la qualité de l’injection dans le 
muscle tibialis. Pour parer à cette variabilité, nous avons décidé de combiner au plasmide 
rapporteur cible du siRNA_NPPRV1, un autre rapporteur qui lui est insensible. Ainsi, il nous 
sera possible de normaliser le signal d’une souris à l’autre. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 : Schéma de la construction préparée pour l’imagerie in vivo. La séquence cible du 
siRNA_NPPRV1 est placée directement en amont de la séquence ARNm du gène de la 
Firefly luciférase. L’expression est contrôlée par le promoteur du cytomégalovirus humain 
(pCMV). 
 
Tableau 1 : Validation de la construction du gène rapporteur placé en aval de la séquence 
cible du siRNA. Les résultats sont exprimés en unités de luminescence relatives, le contrôle 
positif étant le plasmide d’origine du gène de la luciférine (pGL4.51) et le contrôle négatif 
étant les cellules non transfectées. 
 
 pGL4.51 
(100 ng) 
psiRNA-Fluc 
(100 ng) 
Contrôle 
négatif 
 24h 48h 24h 48h 24h 48h 
20 pmole siRNA NPPRV1 16924 3183 13672 2584 134 174
20 pmole -siRNA IR* 26527 7440 634592 92659   
40 pmole siRNA NPPRV1 17954 6166 9592 2344   
40 pmole-siRNA IR 21335 3047 257299 72207   
*IR: irrelevant 
Séquence cible du 
siRNA NPPRV1  
Gène Luciferase-2  
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Après une revue exhaustive de la littérature, notre choix pour le deuxième gène rapporteur, 
tenant compte de nos contraintes (deuxième marqueur luminescence, n’interférant pas avec la 
mesure de la Firefly luciférase), s’est porté sur la Rénilla luciférase. Un plasmide commercial 
a été acquis et évalué in vitro puis in vivo. Nous avons pu alors montrer que la normalisation 
pouvait être effectuée (Fig. 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 : Mesure de la co-expression des gènes Renilla (en haut) et siRNA_NPPRV1-Firefly 
luciférase (en bas). Les plasmides d’expression ont été mélangés puis injectés dans le muscle 
tibialis. On constate une bonne corrélation des deux signaux lorsqu’il y a expression (partie 
droite du graphe représentant en abscisse le niveau d’expression Renilla et en ordonnée, le 
niveau d’expression Firefly). 
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Cet essai nous incite désormais à faire une construction plasmidique unique contenant les 
deux cassettes d’expression de sorte à éliminer tout risque d’expression différentielle entre les 
deux plasmides mélangés. Une fois cette construction faite et validée in vivo, nous serons en 
mesure de mettre en œuvre un nouvel essai de délivrance de siRNA in vivo. 
 
4. Discussion générale et conclusion 
La délivrance in vivo des siRNA est le point critique pour franchir l’espace qui sépare 
l’identification d’une séquence active à un produit thérapeutique. Les quelques publications 
décrivant des essais réussis sur gros animaux sont rares. Chez l’homme, il y a moins de 6 
essais cliniques en phase II pour une délivrance systémique de siRNA qui sont actuellement 
engagées.  Lorsque nous avons tentés de délivrer un siRNA in vivo chez la chèvre, en se 
basant sur les données de la littérature, nous n’avons pas obtenu d’effet significatif. Cela est 
du probablement à l’incapacité de nos systèmes de délivrance à protéger le siRNA de sa 
dégradation ou de sa dispersion dans l’organisme, ou son efficacité insuffisante dans 
l’adressage du siRNA dans le cytoplasme des cellules cibles. Toutes ces hypothèses 
soulignent la nécessité de continuer à travailler sur la qualité de systèmes de délivrance et de 
développer un outil d’évaluation in vivo de ces systèmes de délivrance. 
 
Dans cette thèse, nous avons développé deux nouveaux systèmes de délivrance qui se sont 
avérés in vitro plus efficaces que ceux que nous avions testés précédemment sur la chèvre. Par 
ailleurs, un partenariat noué avec le secteur privé nous a permis d’avoir accès un troisième 
système de délivrance, également prometteur dans notre approche puisqu’ayant déjà fait ses 
preuves chez la souris dans un autre modèle. Les trois systèmes de délivrance sont des 
candidats jugés très intéressants pour une approche in vivo. 
 
Plusieurs raisons nous ont amené à penser à un modèle souris pour tester ces systèmes de 
délivrance. En premier lieu, l’administration de siRNA sur l’espèce cible, le petit ruminant est 
très couteux lorsqu’il s’agit d’administrer du siRNA synthétisé chimiquement (de l’ordre de 
1.700 euros les 3 milligrammes de siRNA). Sur la souris, les quantités sont bien évidemment 
considérablement réduites (40 µg/souris). Par ailleurs, l’évaluation de l’efficacité de la 
délivrance chez l’espèce cible ne peut se faire que par épreuve virulente avec le virus PPR ce 
qui pose des questions d’éthique lorsqu’il s’agit de sacrifier un grand nombre d’animaux. En 
outre, la souris est un animal facile à imager, ce qui permettait d’envisager un modèle 
dynamique de suivi de l’activité interférente chez le même animal, permettant à nouveau de 
réduire le nombre d’animaux nécessaires à l’expérience. Enfin, nous avons opté pour le 
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développement d’un modèle non infectieux chez la souris permettant d’éviter à l’animal la 
souffrance liée au développement d’une maladie systémique dans le but de comparer 
différents systèmes de délivrance. Cette première étape sera cependant suivie d’une seconde 
toujours chez la souris afin d’évaluer le meilleur système de délivrance dans le contexte d’une 
épreuve infectieuse. Toutefois, les essais d’épreuve virulente sur souris seront limités à 
quelques systèmes de délivrance, les moins bons ayant été écartés en phase 1. Ce modèle 
d’épreuve sur souris nécessite la production d’animaux transgéniques sensibles au virus PPR. 
Il est en cours d’acquisition au laboratoire. Il sera un intermédiaire indispensable avant 
passage sur chèvres. 
 
Nos travaux ont permis de montrer que le modèle non infectieux d’évaluation des systèmes de 
délivrance était à portée de main. Il ne reste plus qu’à établir la reproductibilité de ce modèle 
pour ensuite commencer l’évaluation de nos trois systèmes de délivrance. 
 
En conclusion, après avoir été confronté en direct à des difficultés de mise en œuvre de la 
délivrance de siRNA anti PPR chez la chèvre, nous avons engagé un travail de fond pour 
identifier de nouveaux systèmes de délivrance qui s’avèrent très prometteurs, basé soit sur un 
vecteur viral, soit sur un peptide, soit sur une préparation à base de liposomes, couvrant ainsi 
assez largement les systèmes déjà testés avec succès dans d’autres modèles d’atténuation de 
l’expression de gènes in vivo. Par ailleurs, nos efforts pour le développement d’un modèle in 
vivo ont été fructueux, dans un domaine où les compétences du laboratoire étaient inexistantes 
au début de cette thèse. L’état d’avancement de ce projet, même s’il n’a pas permis d’arriver à 
montrer une efficacité in vivo de notre siRNA, offre désormais des perspectives de résultats à 
court terme. C’est la contribution majeure de ce travail. 
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INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peste des petits ruminants (PPR) is an infectious and highly contagious viral disease of 
domestic and wild small ruminants, clinically characterized by pyrexia, pneumonia, oral 
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erosive lesions, occulo-nasal discharges, and diarrhoea. Morbidity rate of 90% and mortality 
rate of 50–80% may occur in susceptible populations. The disease transmission occurs 
primarily through the aerosols from infected animals in close contact with healthy animals. It 
is caused by the virus of Peste des Petits Ruminants (PPRV), which belongs to the genus 
Morbillivirus and family Paramyxoviridae. Goats and sheep are the primary targets of the 
virus, however, gazelles, ibex and deer are also susceptible to the disease [2]. Furthermore, 
unapparent infections in cattle, buffalo, and camels have been reported [3-5]. 
 
PPR is an emerging trans-boundary disease, which has apparently spread from its original 
place of discovery in West Africa (Côte d'Ivoire) to East Africa, Middle East, and South Asia 
[6-10]. PPR is presently extending its traditionally boundaries and has reached Tibet and 
Tajikistan on one hand and on the other hand has recently emerged in Turkey, Morocco and 
Tunis, thus threatening Europe [11-15]. It is on the list of animal diseases that must be 
declared, in case of an outbreak, to the World Organization for Animal Health (Office 
international des epizooties, OIE). The economic losses are due to mortality, loss of 
productivity in sick animals, treatment costs and ban on the international trade once the 
disease is declared.  
 
Morbilliviruses are important pathogens of humans, ruminants, carnivores and marine 
mammals characterized by their high contagiosity and severity of the disease. Good vaccines 
inducing long-term immunity are available against measles, rinderpest (RP), peste des petits 
ruminants (PPR) and canine distemper (CD). However, the vaccination coverage is only 
partial and recurrent outbreaks of measles, CD and PPR are observed. No specific treatment is 
available when the disease appears and serious and definitive after-effects can develop 
particularly of the nervous system [16, 17]. Therefore, an antiviral therapy could be useful not 
only in the treatment, control and eradication strategies against PPR, but it will also have 
implications for diseases caused by other morbilliviruses.  
Since its first discovery in 1998, the phenomenon of RNA interference (RNAi) has been 
successfully used against many viruses in vitro, both through chemical and viral vectors. 
RNAi can be used as an effective mean for antiviral therapy if well delivered into the cells. 
However, efforts for in vivo delivery have been facing similar obstacles as gene therapy since 
1980s, i.e., low bioavailability, non-specificity, toxicity, low transfection efficiency of 
chemical vectors in presence of serum, and immunogenicity of viral vectors.  
With the aim to develop an antiviral strategy against these diseases, various siRNA sequences 
were designed at CIRAD, to target the nucleoprotein (N) gene of peste des petits ruminants 
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virus (PPRV), rinderpest virus (RPV) and measles virus (MV) which could effectively inhibit 
viral replication, N protein expression and copies of viral genomes in vitro. However, 
therapeutic application of siRNA requires correct delivery of these molecules to the cell 
cytoplasm which poses significant problems in vivo. To overcome these problems several 
delivery strategies have been developed, like those based on chemical vectors transfecting 
siRNAs (small interfering RNAs) as well as those based on viral vectors expressing nucleic 
acids [18]. Although siRNAs have been successfully delivered against viral infections by 
local administration [19], the systemic delivery of siRNAs is still a major stumbling block for 
the use of siRNAs to therapeutic use. The siRNAs have been successfully delivered 
systemically through chemical vectors against hepatitis B virus (HBV) [20], hepatitis C virus 
(HCV) [21], and HIV [22], but these involved the murine models. Whereas viral vectors have 
been used to inhibit infections of farm animals with some success. Adenoviral vector 
expressing shRNA against FMDV has been used in swine [23], while recombinant 
herpesvirus of turkey (HVT) [24] and avian leukosis virus-based retroviral vectors [25] 
targeting the Marek’s disease virus (MDV) have been able to moderately reduce viremia in 
chicken. Thus far, no work has been reported on in vivo delivery of siRNAs against 
morbilliviruses. 
 
The present work is divided in two parts. The first part concerns the review of literature about 
PPR, RNAi, and vectors used for siRNA delivery. The second part concerns the results 
obtained in the course of the research project. This second part is divided in three sections and 
ended by a general discussion. 
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1. Peste de Petites Ruminants (PPR): A Morbillivirus infection 
Peste des petits ruminants virus (PPRV) shares many similarities with the diseases caused by 
other viruses in the Morbillivirus genus, not only in terms of structure but also in its 
pathogenesis and epidemiology. Therefore, first of all, there will be a general review about 
morbillivirus classification, economic importance, epidemiology, and structure while in the 
later part will be reviewed the PPR itself. 
 
 1.1 Classification 
The morbilliviruses make up an antigenically homogenous group in the family 
Paramyxoviridae. The viruses belonging to the Morbillivirus genus are negative sense, single 
stranded, non segmented RNA viruses which are classified into the order Mononegavirales, 
family Paramyxoviridae and sub-family Paramyxovirinae. In addition to PPRV, the 
Morbillivirus genus includes measles virus (MV), dolphin and porpoise morbilliviruses 
(DMV & PMV), canine distemper virus (CDV), phocine distemper virus (PDV), and 
rinderpest virus (RPV). Morbilliviruses can infect a wide variety of hosts like primates, 
ruminants, carnivores and marine mammals with devastating ecological, demographic and 
economic consequences. In general, each morbillivirus infects only one order of mammals to 
cause serious disease (Fig. 1), however, these viruses can extend host range by jumping the 
species barrier. Thus RPV infects artiodactyls, PPRV infects sheep and goats, MV infects 
primates, CDV infects young canines, felines, and phoques, and two new members of 
Morbillivirus genus, the DMV and PMV affect dolphins and porpoises, respectively. 
Moreover, each of the morbilliviruses can be also further classified into several distinct 
phylogenetic lineages.  
 
Figure 1: Phylogenetic tree showing the relationships between the different morbilliviruses 
based on partial sequence of the phosphoprotein (P) gene, according to Barrett et al., 2006 
[26]. 
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1.2 Morbillivirus infections: Geographical distribution, epidemiology and economic 
impact 
Morbilliviruses share many similarities. They are primarily lymphotrophic and secondarily 
epitheliotropic. They use CD150 or signaling lymphocyte activation molecule (SLAM), found 
on lymphocytes, monocytes, and dendritic cells, as a primary receptor [27]. Each virus in the 
Morbillivirus group has a single serotype, and the individuals surviving infection generally 
develop long lived immunity involving cell mediated immune response [28]. However, 
despite being antigenically conserved, they are genetically variable and have mutation rates 
similar to other RNA viruses [29]. There is no carrier state; therefore all morbilliviral 
infections require a constant supply of susceptible hosts for maintenance continuity of chain 
of transmission for the infection. Through mathematical models it has been estimated that at 
least a susceptible population of 250,000-500,000 is needed to MV and RPV maintain MV 
and RPV infections [30-32].  
 
Morbilliviral infections have plagued human and animal populations since centuries. Among 
the group, rinderpest (RP), also called cattle plague, is the oldest, best documented, and most 
dreaded disease of farm animals, with descriptions of the disease in Europe dating back to late 
Roman times [33]. The disease originating in Asia spread to Europe, Africa towards the end 
of nineteenth century, Brazil in 1920 and Australia in 1923 [34]. Being highly infectious and 
with about 90% mortality rate, it caused terrible destruction of cattle, affecting agriculture and 
rural livelihoods bringing famine and starvation. Outbreaks of RP in Europe in 1920s lead to 
creation of OIE in 1932 [35]. The disease in Europe was controlled by early twentieth century 
through zoo-sanitary measures except for few introductions due to importation of infected 
cattle and zoo animals [36]. However efforts were made to develop a vaccine, and it was not 
until 1962 that a safe tissue culture derived attenuated vaccine was developed [37]. Despite 
various attempts at controlling the disease with vaccinations, the disease resurged many times 
[36]. In 1994, Food and Agriculture Organization (FAO) launched “Global Rinderpest 
Eradication Programme (GREP)” in association with World Organization for Animal Health 
(OIE), and donor agencies, for control and eradication of rinderpest through vaccination 
campaigns. The programs of vaccination followed by sero-monitoring were very successful 
and last outbreak of RP was reported in 2001. The vaccination has been stopped since 2007 
and FAO is in the process of ending the field operations. An international declaration of 
Global Rinderpest Freedom is expected to be made by 2011. After smallpox in humans, this 
would only be the second time in history that a disease has been eradicated worldwide [38]. 
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Figure 2:  The Global Rinderpest Eradication Programme. Status report on progress made to 
May 2010 in the eradication of rinderpest: highlighting success stories and actions required 
prior to Global Declaration in 2011. According to FAO [38].  
 
RPV has been suggested to be the morbillivirus archetype [39]. Measles virus is closely 
related to the RPV, therefore it is assumed that MV probably evolved in an environment 
where cattle and humans lived in proximity [26, 40] and that may have been after a start of 
livestock farming in the early centers of human civilization in the Middle East [41]. However, 
using phylogenic techniques based on sequences of haemagglutinin (H) and neuraminidase 
(N) genes, it has been estimated that divergence between MV and RPV occurred more 
recently around 11th and 12th centuries [41]. Despite availability of an effective vaccine since 
1963, measles outbreaks still occur in poorly vaccinated areas of Asia, Africa, and even 
Europe and more than 30 million cases of acute measles with approximately 345,000 cases of 
infant deaths are annually reported [42]. “European Region strategic plan 2005-2010” of 
WHO, which included a target for eliminating measles, has not been achieved as measles 
cases have been reported even in March 2010 with an outbreak in Ireland and Slovenia  [43]. 
South Africa has also experienced a large measles outbreak with 17,354 laboratory-confirmed 
measles cases diagnosed during the period January 2009 to August 2010 and despite a 
nationwide mass measles vaccination campaign new cases continue to be confirmed 
throughout the country [44]. Even in the months of August and September 2010, cases been 
reported in ProMED-mail (International Society for Infectious Diseases) for measles in India, 
Zimbabwe, and Brazil [45-47]. 
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Figure 3: Number of reported measles cases with onset date from Feb 2010 to Sept 2010 
[44]. The number of reported cases of measles reflects a small proportion of the true number 
of cases occurring in the community. Many measles cases do not seek health care or, if 
diagnosed, are not reported thus the data shown in the map under-represents the true number 
of cases, particularly those occurring in the last one to two months. 
 
Canine distemper (CD) is a fatal disease for many domestic as well as wild carnivores with an 
ability to cross species barrier. It has a global distribution with seven phylogenetic lineages 
found in Arctic, America, Europe, Asia, and Africa [48]. CD shares some antigenic and 
taxonomic similarities with measles virus, but it is assumed to have emerged much more 
recently [29]. Effective vaccines are available but resurgences of canine distemper have been 
reported even in vaccinated dogs [49, 50]. The haemagglutinin (H) protein of the virus 
interacts with host cell receptors for morbillivirus attachment and this protein of CD has a 
higher mutation rate as compared to mumps and measles  [29]. This partly explains a broader 
host range for CDV as compared to other morbilliviruses. Furthermore, after mapping of the 
distribution of mutations sites on H protein of CDV isolates from new host species, it has 
been found these are not only to be under influence of positive selection but also that the 
majority of amino acid substitutions fall into the SLAM-binding domains of the H protein, 
which are responsible for host specificity [51, 52].  
 
PPR was first described by Gargadennec & Lalanne in 1942, as an outbreak in Côte d'Ivoire, 
they reported it to be a highly fatal disease and resembling rinderpest but affecting only sheep 
and goats while cattle remained unaffected [6]. PPR was later found in Senegal in 1962 [53]. 
WHO 
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Although PPR is a recently recognized disease, the disease probably already existed but 
diagnosis was perhaps confused with rinderpest and pasteurellosis [54]. Since, small 
ruminants are less susceptible to even more virulent strains of RPV and the infection tends to 
be either sub-clinical or mild thus perhaps even some of the reported RP outbreaks in small 
ruminants in past may have been due to PPRV [55]. Mornet et al., had reported in 1956 that 
virulent strains of PPRV was not pathogenic for cattle but conferred immunity against RP 
[56]. Based on these results the authors suggested that PPRV can be considered a variant of 
RPV, better adapted to the small ruminants. Serologic cross-reactions with RPV also confused 
early recognition of the disease as a distinct entity of separate etiology, however by late 1970, 
experimental infections, virological studies, and serologic studies established that PPR was a 
disease distinct from RP [57-59]. The two viruses were definitively differentiated by 
biochemical tests as well in 1987 [60]. Until 1979 this disease was declared to be limited to 
West and central Africa [61], however it was reported in 1984 that apparent RP outbreaks in 
1972 and 1973 in Sudan were later serologically confirmed as PPR [7]. By 1990s, it was also 
reported in East Africa in Kenya [8] and Uganda and Ethiopia [62]. Outside Africa, the PPR 
was first discovered in southern India in 1987 [9] and later on it spread across Arabian 
Peninsula, Middle East and the remaining subcontinent by 1995 [10]. PPR still continues 
extending towards areas that were not previously endemic, and it was declared in Tibet, China 
in 2007 [11] and Morocco in 2008 [15] and has also been reported in Tunis [14].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Geographical distribution of the phylogenetic lineages of PPRV. [63] 
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PPRV found in different geographic areas has been differentiated into four (1–4) lineages 
based upon nucleic acid sequencing (Fig. 4). The apparent rapid spread of PPR during the last 
three decades is perhaps due to a combination of factors like greater trade of live animals, 
wider availability better diagnostic tools, vigilance and more awareness after eradication of 
RP [64]. Furthermore, it has also been postulated that the chronological spread of PPR from 
West Africa to Bangladesh may give a false impression that the disease spread has occurred 
from West to East and that perhaps PPRV like RPV also has its origin in Eurasia and has 
spread towards the West [37].  
 
The economical impact of PPR is greatest on the poorest populations. Since large ruminants 
are costly, a large proportion of rural populations breed sheep and goats for subsistence. The 
small ruminants are therefore considered to be the “cattle of the poor”. Not only are the goats 
and sheep raised as a source of meat and milk for family consumption, but they are also an 
important source of income. In an international study aimed at prioritizing research on animal 
diseases in order to have maximum impact on improving conditions in developing countries, 
highlighted the economic importance of goats and sheep for the poor and ranked them at first 
or second position for Asia and Africa [65]. Furthermore, the PPR was ranked among the top 
ten diseases in these animals and thus affecting livelihoods of the poor in Asia and Africa. It 
thus showed a need for the control of PPR to be taken into consideration for any poverty 
alleviation policies [65]. PPR is one of the priorities of FAO Emergency Preventative System 
(EMPRES) program which considers more than a billion small ruminants to be at risk of 
PPRV infection  and the rate of global domestic small ruminant population to be at risk was 
62.5% [66, 67]. A socioeconomic study by Emergency Centre for Trans-boundary Animal 
Diseases (ECTAD) of the Food and Agriculture Organization (FAO) of the United Nations, 
conducted to understand the livelihood impacts of PPR in the arid and semi-arid lands of 
Northern Kenya, found that PPR outbreaks resulted in better-off farmers slipping into poverty 
and the poor and very poor became destitute [68]. The livestock-derived income losses due to 
PPR ranged between 21% and 99 % and it was found that most households were unable to 
maintain sustainable flock size owing to high mortality. Therefore, they had to leave 
pastoralist livelihoods resulting in a long term dependency on food aid and a drain on national 
resources [68]. Eradication of rinderpest has increased the relative economic importance, thus 
highlighting the need for PPR control.  
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1.3 Morbillivirus genome, structure and replication 
The PPRV shares structural, biological, antigenic and molecular features in common with 
other morbilliviruses. Morbilliviruses are enveloped, pleomorphic, single stranded, negative 
sense RNA viruses. When viewed by electron microscopy, the members of Paramyxoviridae 
family are indistinguishable [69]. The virion of RPV attains a maximum diameter of about 
300 nm while PPRV tends to be larger, having a mean diameter of about 400-500 nm [58, 
70]. The viral particle consists of an outer lipid envelop and an inner ribonucleoprotein (RNP) 
core. The RNP core comprises of the viral genome encapsidated by nucleocapsid protein. The 
RNP complex, but not the naked RNA genome, acts as a template for both transcription and 
replication [71]. Typically, morbillivirus genome is made up of about 16,000 nucleotides, the 
genome of PPRV being 15,948 bases in size, and is organized into six contiguous 
transcriptional units encoding six structural and two non-structural viral proteins [72]. The 
structural proteins are nucleocapsid 
(N), phosphoprotein (P), matrix (M), 
fusion (F), haemagglutinin (H), and an 
RNA-dependent RNA polymerase 
(RdRp) also called large (L) protein. 
While non-structural proteins are (C) 
and (V) which are transcribed by the P 
gene using alternative expression 
strategies and are found in cytoplasm 
of infected cells. The internal proteins 
(N, P and L) make up ribonucloprotein 
and play a role in replication and 
protection of viral genome while the 
external proteins (M, H and F) traverse 
the host cell derived lipid envelop and 
interact with host cells to transmit viral 
genome in to the cell [69]. 
 
 
 
 
 
Figure 5: (a) Morbillivirus structure and (b) genome organization (Modified, according to 
Moss et al., 2006 and Bailey et al., 2005 [1, 72]). 
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The viral genome has on its 3’ and 5’ ends two untranslated regions (UTRs), called “leader” 
or genomic promoter (GP) and “trailer“ or anti-genomic promoter (AGP), which control viral 
transcription and replication. The GP is required for both transcription of virus mRNAs and 
transcription of a full-length positive sense virus genome, which is a replicative intermediate, 
while the AGP is responsible for the production of full length negative sense genomes. For 
PPRV, the leader region comprises a total of 107 nucleotides with 54 nucleotides being on the 
3’-UTR region of the genome followed by a stretch of 53 nucleotides at the 3’ UTR of N gene 
[69, 72]. Whereas in case of PPRV the trailer is made of up 109 nucleotides, with 69 
nucleotides at the end of the L gene followed by 40 nucleotides at the 5’UTR region. [69, 72]. 
Between the 3’ and 5’ ends lay the six transcription units which transcribe 8 viral proteins in 
the sequences of 3’–N-P/C/V-M-F-H-L-5’. Each of the transcription unit starts by a 
conserved sequence (UCCU/C) and ends with a polyadenylation signal and poly uracyl of 6 
nucleotides [69]. The transcriptional units are separated by a conserved inter-genic 
trinucleotide 3’-GAA sequence between all viral genes except for the H and L genes where it 
can be GCA (MV, RPV and PPRV cote d’Ivoire/89 strain), or GAA (PPRV Turkey/2000 and 
the vaccine strains) and also between the L and the trailer sequence where it may be replaced 
by GAU (PPRV) or GUU (CDV, PDV and DMV) [69, 72]. These tri-nucleotide sequences 
are called mRNA pause signals for transcription as these sequences themselves are not 
copied. 
 
1.3.1 Viral Proteins 
 
1.3.1.1 Nucleoprotein (N) 
N protein of morbilliviruses is a major viral protein both in the virion and in the infected cell 
[73]. It is highly antigenic, generating a humoral immune response [74]. Therefore many of 
the antibody based diagnostic tests rely upon its antigenic characteristics. Morbillivirus N 
proteins consist of 525 amino acid residues in RPV, MV and PPRV, but only 523 amino acids 
in CDV, DMV, and PMV and have a molecular weights ranging from 60 to 68 kDa [69]. The 
N gene of PPRV comprises 1,685 nucleotides, with 1,576 nucleotides coding for N protein 
composed of 525 amino acids and a molecular weight of about 60 kDa [60, 75]. The N gene is 
the most conserved among the Morbilliviruses genus [76] and the N protein is also the most 
conserved among viral proteins [72]. It is a structural protein which encapsidates the viral 
genome into an RNAse-resistant nucleocapsid (the template for RNA synthesis) and together 
with P protein forms the RNP, which constitutes the minimum essential for transcription and 
replication of viral genome in the cell cytoplasm [77].  
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1.3.1.2 Phosphoprotein (P) 
It is one of the three components of the RNP and plays an important role in transcription and 
viral replication. The morbilliviral P protein is made of 506 to 509 amino acids, and has a 
molecular weight ranging from 72–86 kDa  [60]. P protein of PPRV is the longest (509 amino 
acids) while the DMV counterpart is the shortest in DMV (506 amino acids) and MV, RPV, 
CDV and PDV have 507 amino acids [69]. It is a multifunctional protein which binds both the 
N and L proteins and acts also as a chaperon keeping the N in a soluble form to enable 
encapsidation and binding with the newly synthesized genomic RNA [52]. It is also an 
essential co-factor for L protein in its RdRp function [78]. P is one of the least conserved 
morbillivirus proteins [79]. 
 
1.3.1.3 V & C Proteins 
In addition to producing the P protein, the P gene encodes the V and C proteins, via an RNA 
editing process and an alternative initiation of translational within a different reading frame, 
respectively [80, 81]. The C protein plays a role in the transcription, while the V protein plays 
its part in replication of viral genome. Moreover, the two proteins have a role in morbilliviral 
virulence as they interfere with the innate immunity by blocking interferon response by the 
host cells [78, 82]. 
 
1.3.1.4 Matrix (M) protein 
It is a small protein with 335 amino acids and is the most conserved within the group. The 
morbillivirus M protein plays an important role in assembly of viral particles subsequent to 
transcription. [83]. It favors viral particle formation by retaining the viral RNP complex at the 
plasma membrane through interaction with the N protein, negatively down regulating 
transcription, and membrane fusion and thus promoting virus budding [84]. It associates with 
the inner surface of the plasma membrane [85] as well as the cytoplasmic tails of the H and F 
glycoproteins [85-87] on the one hand and with the RNP complexes in the cytoplasm on the 
other hand, to bring theses virus components together at the cell surface to make new viral 
particles [88].  
 
1.3.1.5 Fusion (F) Protein 
F is one of the two viral surface glycoproteins, made of 546 amino acids, which is embedded 
in the envelope and protrudes as spikes. It mediates fusion of the viral and cellular membranes 
at the cell surface and thus helps liberating nucleocapsid into the cell cytoplasm. However, 
before fusion can take place, morbilliviruses, except PPRV, must first attach to the host cell 
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receptor through its H protein, which also acts as a fusion promoter [89]. While the F of 
PPRV is capable of inducing fusion independent of H protein [89]. The translated F0 protein 
is in an inactive form which is cleaved by host cell proteases into the F1 and F2 subunits. The 
F1 subunit is hydrophobic and has the fusogenic properties [78]. While the virus replicates, 
expression of the synthesized F protein on the host cell surface results in fusion with the 
neighboring cells to form syncytia, which are the characteristic cytopathic effect of 
morbilliviruses [77]. Cell to cell fusion plays an important role in the propagation and 
pathogenicity of the virus. While propagating both by virus release and reinfection, the F 
protein on the host cell surface serves as a surface protein for the newly synthesized virus 
particles when they obtain envelops upon budding [77]. 
 
1.3.1.6 Haemeagglutinin (H) Protein 
It is a transmembrane glycoprotein which protrudes from viral envelope and enables 
attachment of virus to the membrane receptors of the host cells. It mediates the interaction of 
the virus with the cellular receptors. In association with the fusion (F) protein, the H protein 
forms the envelope protein complex that is used for both virus attachment and membrane 
fusion. The H protein consists of 604 amino acids for DMV, 617 amino acids for MV and 
RPV and 609 amino acids for PPRV and RPV [69]. The H protein of PPRV and RPV is 
distinct in the morbillivirus group, as it possesses both the haemagglutinating and 
neuraminidase activities [90, 91]. Being a surface protein, the H of morbilliviruses is highly 
antigenic and the principal target of neutralizing antibodies. [92]. Therefore, it has to evolve 
to escape host immune responses and thus maintain the virus in the susceptible population. 
Antibodies to H protein are the second most abundant after the N protein [74]. However, N is 
an internal protein thus antibodies against it are not neutralizing [77]. The fact that H gene is 
not highly conserved, probably also reflects the role of H in binding to host cell receptors and 
thus playing a part in host-switching [52]. In the morbillivirus group, CDV has a 
comparatively wider host range and new viral variants are being found out [93]. The H gene 
of CDV has been found to have a much higher mean substitution rate (11.350 x 104 
subs/site/year) as compared to measles and mumps (6,585 x 104 and 9,168 X 104 
subs/site/year, respectively) [29]. It has been suggested that evolution at residue 530 and/or 
549 in the SLAM-binding region of the H protein of CDV is associated with disease 
emergence in novel host species [51, 52].  
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1.3.1.7 Large (L) protein 
It is the largest of the morbillivirus proteins having 5,183 amino acids and a molecular weight 
of about 200 kDa. It is also the least abundant viral protein as it is the last to be transcribed. 
Despite having a large size, the L protein is highly conserved among morbilliviruses. It 
functions as RdRp in association with P protein. It performs a major role in genomic RNA 
transcription and replication as well as the nucleotide polymerization, capping, methylation 
and polyadenylation of viral mRNAs [78, 94].    
 
1.3.2 Viral mRNA synthesis and replication of genome  
Upon encountering the susceptible host cell, the viral H protein interacts with the SLAM 
receptor molecule on the cell surface for attachment, while the F protein inserts its fusogenic 
domain into target cell membrane, thus initiating the membrane fusion process which is 
needed for entry of viral core complex into the host cell [95]. Thus the viral ribonucleoprotein 
core enters cell cytoplasm where it has to replicate. However because of being negative sense 
viruses, the genomic RNA of morbilliviruses can not be directly translated for production of 
viral proteins. Therefore, it is first transcribed into messenger RNAs (mRNAs) with the help 
of viral RdRp, which are then translated by cellular machinery to produce viral proteins. 
However, it is still unclear as to how RdRp accesses the template RNA which is strongly 
associated with N protein [69].  The viral transcription is initiated by RdRp after attachment 
to the GP of the viral genome. The viral genes are transcribed sequentially in a “progressive 
start-stop mechanism” in which, upon encountering a stop codon of a gene and a subsequent 
intergenic tri-nucleotide, which acts as a pause signal, the synthesized copy of RNA detaches 
and RdRp then moves on to the next gene. Thus are transcribed the monocistronic mRNA 
molecules, however occasionally the polymerase does not respect one or two inter-genic 
pauses, and this aberrant transcription results in synthesis of bi or tricistronic mRNAs. This 
progressive “stop-start” mode of transcription by RdRp also produces a gradient in the 
quantity mRNA produced from different morbillivirus genes. This happens because if RdRp 
becomes detached from RNP template during the transcription, which is frequent at gene 
junctions, it has to return again to the GP to reinitiate transcription. Owing to this 
morbillivirus genomic organization, more a gene is away (far) from the viral promoter, less it 
is transcribed [69]. The transcriptional gradient in protein production corresponds to the 
different quantities of various viral proteins needed for synthesis viral particles. Thus N 
protein is the most abundant while L protein is the least produced of the viral proteins (Fig.5).  
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Figure 6 : Measles virus replication cycle. (according to Moss et al., 2006) [1] 
 
 
Once sufficient viral proteins have been generated, gene junctions are ignored by the RdRp, 
mRNA transcription is stopped and assembly of a full-length, positive sense antigenome is 
started. The precise mechanism responsible for switching from a transcriptive to the 
replicative mode is not fully established. The antigenome, like genomic RNA, is also 
encapsidated and it serves as a matrix for synthesis of new copies of negative sense genomic 
RNA.  
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1.3.3 Replication of viral genome, assembly and release of the viral particles 
The virus assembly involves association of free N subunits with newly synthesized viral 
genomic RNA. Next is formed the association between P-L protein forming a complex that 
binds with N-RNA, resulting in formation of RNP complex [77]. The H and F proteins are 
transported to the surface of cell membrane for incorporation on the outside of the envelope 
for the newly budding virions. While the M protein plays the role of a bridge, by associating 
on the one hand with the surface of plasma membrane, and cytoplasmic tails of the H and F 
glycoproteins, and on the other hand it also interacts with RNP complex [96]. Finally the 
interaction between viral H and F proteins on the cell membrane and RNP causes the 
membrane to envelope the particle and a new virion is liberated into external environment by 
budding. This process of budding does not kill the host cell thus allowing for (re-infection 
and) formation of more viral particles.  
 
1.3.4 Host immune response 
The specific antibodies may be detectable within a week of infection [97, 98] and the immune 
response is directed against all viral proteins. The most rapid and abundant antibodies 
produced by the host during an outbreak are directed against the N protein, most likely 
because of the location of the N gene at the 3′-end of the genome, the start–stop mechanism of 
the RNA-dependent RNA polymerase [99] and because the N protein is the major structural 
viral protein [73]. Antibodies to the morbillivirus N protein account for most of the 
complement-fixing activity [99], while virus neutralizing (VN) antibodies are mostly directed 
against the H glycoprotein and, to a lesser extent, against the F protein [99, 100]. Moreover, 
maternal antibodies are also transmitted to the neonates via colostrum and can protect 
newborns against RPV and PPRV for up to six months [101, 102]. Cell mediated immunity 
also plays a role against morbilliviral infections and the studies in CDV and MV show a role 
of cytotoxic T cells in convalescence, an immunity obtained by activation of CD4+ and CD8+ 
lymphocytes. A vaccination against RPV, by a Plowright vaccine strain (RBOK) of RPV [37], 
was found to produce a strong CD4 T cell response [103].  
 
Although morbillivirus infections generate strong immune responses with resulting long term 
immunity, paradoxically, during temporary phase post-infection they also produce an 
immunosuppression with the emergence of secondary infections [104, 105]. PPRV infection 
in small ruminants also produces an impairment of cellular and humoral immune functions, 
resulting in frequent opportunistic infections [106, 107]. The leucopenia and 
immunosuppression result from a combination of factors like cell death caused by infection of 
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lymphocytes and apoptosis, and the cell cycle arrest, caused by exposure to the viral 
haemagglutinin and fusion surface glycoproteins as well as viral nucleoprotein, expressed 
from the damaged cells [106-108].  The immune suppression is not only observed in case of 
natural infections but also after vaccination with attenuated morbilliviruses [103, 109, 110]. 
 
2. Peste de Petites Ruminants : The disease, its diagnosis and control 
The disease has been differently named as Kata, goat plague, pseudo-rinderpest, 
pneumenteritis complex and stomatitis-pneumoenteritis syndrome. However its French name 
has been finally adopted as Peste des Petits Ruminants (PPR). Peste des petits ruminants 
(literally meaning plague of small ruminants) is an acute viral disease of small ruminants 
clinically characterized by fever, occulo-nasal discharges, stomatitis, diarrhea and pneumonia 
with foul offensive breath [99]. Clinical signs are very similar to those of rinderpest.  
 
2.1 Host range 
PPR is primarily a disease of small ruminants i.e., sheep (Ovis aries) and goats (Capra 
hircus). Goats are more susceptible to the disease which causes heavy losses, while it can be 
occasionally severe in sheep [84]. However, susceptibility varies in different breeds. Apart 
from domestic small ruminants, PPR has also been confirmed in captive wild ungulates 
comprising gemsbok (Oryx gazelle), Dorcas gazelle (Gazella dorcas), Nubian ibex (Capra 
ibex nubiana), Laristan sheep (Ovis orientalis laristanica), and Nilgai (Boselaphus 
tragocemalus) [2]. Experimentally, the American white-tailed deer (Odocoileus virginianus) 
is fully susceptible [111]. The only case of wild animal being seropositive with PPRV is that 
of African grey duikers (Sylvicapra grimmia) which were found to be seropositive in Nigeria 
[112]. PPR is primarily a disease of small ruminants, but infected cattle, buffalos, and pigs 
that develop unapparent infections and seroconversion are considered as epidemiological 
dead-ends. However, PPRV virus was isolated from pathological samples in buffaloes in 
India [5]. Camels in Ethiopia and in Sudan showed clinical signs of the disease and proved to 
be infected by PPRV [3, 4]. 
 
2.2 Transmission  
The infected animal can excrete PPRV in discharges about 24-48 hours before onset of 
clinical signs [97, 113]. The secretions from eyes, nose and mouth as well as feces contain 
large quantities of the virus [113]. In an experimental infection of goats with PPRV, virus 
could be detected in ocular secretions on day 2 and in nasal and oral secretions on day 3 post-
infection through RT-PCR [91]. Since the virus cannot survive long outside the host body and 
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the fact that upper respiratory tract is the entry point of the virus in to the host, close contact 
of infected animal with the susceptible animals is an essential requirement for transmission as 
described for RPV [114, 115]. The transmission occurs either through inhalation aerosol 
dispersed virus or by ingestion of infected material [116-118]. There is no carrier state. 
 
2.3 Pathogenesis 
Like other viruses in the Morbillivirus genus, PPRV is also lymphotropic and epitheliotropic 
[61]. The viral tropism is also manifested by the clinical signs like occulo-nasal discharges, 
diarrhea, oral erosive lesions, marked immuno-suppression, and leucopenia [119]; while viral 
antigen can be found in lymphoid organs and epithelial tissues of the affected animals [106]. 
The SLAM or CD150 is the primary receptor for PPRV [120], which is found on activated T 
cells, B cells, thymocytes, macrophages and dendritic cells [121, 122]. The viral H protein 
interacts with the SLAM receptor molecule on the cell surface while the F protein inserts its 
fusogenic domain into target cell membrane, thus initiating the membrane fusion process 
which is needed for entry of viral core complex into the host cell [95]. For PPRV infection, 
respiratory route is the portal of entry as is the case of measles. It has been found that in 
primate models as well as in mice expressing the MV receptor human SLAM the sub-
epithelial dendritic cells are initially infected by MV in the air ways [123]. However DCs in 
respiratory epithelium express very low level of CD150 receptors [124]. These DCs express 
C-type lectin called DC-SIGN which has been postulated to have a role in MV capture and 
transmission to the lymphocytes in the regional lymph nodes by in trans–infection 
(independent of de novo synthesis of virus in infected DCs) and also in cis infection (by the 
newly synthesized of viruses in infected DCs) in combination with CD150 receptor [124, 
125]. Similar role of DC-SIGN receptors have also been found in pathogenesis of several 
other viruses like human immunodeficiency virus (HIV) [126] and herpes simplex virus 
(HSV) [127]. Infected DCs also carry partly processed viral antigen to the lymphocytes in the 
lymph glands [42, 128]. The immunological synapse formation, with lymphocytes in the 
lymph glands, enhances viral transmission due to prolonged interactions during antigen 
presentation. Furthermore antigen presentation initially activates them and activated 
lymphocytes expressing greater CD150 are later infected [124].  While primary targets of 
morbilliviruses are the CD150 (SLAM) positive cells, for release from the host in the later 
stages of infection, the virus uses an additional unknown receptor(s) on SLAM-negative 
epithelial and endothelial cells [129, 130]. Interestingly, the epithelial cells are infected 
basolaterally only upon contact with underlying already infected leukocytes [128]. Since, the 
 44  
epithelial cells can only be infected by MV via basolateral surface; role of respiratory 
epithelium in initiation of infection is not an essential pre-requisite [95].  
C  
 
 
 
 
 
 
 
 
Figure 7: Possible strategy used by measles virus to cross epithelium of lung (A) and 
endothelial barriers (B). Antigen presentation and transmission of measles virus by the 
infected DCs to lymphocytes in the lymph glands (C) [42, 95] Modified. 
 
Moreover, after intra nasal inoculation of rhesus monkeys with a recombinant MV selectively 
unable to recognize human SLAM (SLAM-blind), it induced neither clinical signs nor 
significant viremia, proving that efficient SLAM recognition is necessary for viral virulence 
and pathogenesis [131]. Additionally, in experimental infection of ferrets with canine 
distemper virus expressing GFP, it was found that CDV replication in epithelial cells was not 
detectable initially, but was found substantial before death of the host [132]. In the same 
experiment, 40% of T and 60% of B lymphocytes were infected [132].  
 
Even after recovery from PPRV infection, there is a long lasting and important inhibition and 
impairment of cellular and humoral immune functions characterized by immuno-suppression, 
lymphocyte loss and leucopenia rendering animals highly susceptible to opportunistic 
infections [106, 107]. The marked immune-suppression and leucopenia may be due to a 
combination of cell death, caused by infection of lymphocytes and apoptosis, and the cell 
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cycle arrest, caused by exposure to the viral haemagglutinin and fusion surface glycoproteins 
as well as viral nucleoprotein, expressed from the damaged cells [106, 107].   
 
2.4 Gross and microscopic pathology 
Animals dying from the peracute form of PPR do not show any gross pathological findings 
except for congestion of oral mucosa and ileo-caecal valve and occasional oral erosions. 
However, major gross lesions are mostly found after death with an acute form of the disease. 
On digestive system, erosive and necrotic lesions are found on the lips, tongue, gingiva, hard 
palate, and oral mucosa. Occasionally, lesions may be even found on pharynx and erosions on 
the ruminal pillars and abomasum. Congestion of intestinal mucosa, colon, rectum with some 
hemorrhages and thickening of mucosa giving a zebra-stripe appearance, are also observed. 
The gut-associated lymphoid tissues are necrotic and mesenteric lymph nodes and spleen may 
be swollen. Respiratory mucosa is congested with erosions in nares and trachea. There is 
fibrinous or suppurative pneumonia in cardiac and apical lobes of lungs. Pulmonary lymph 
nodes are found swollen and oedematous. In females, vulvo-vaginitis may be seen. Atypical 
renal lesions have also been reported [133].   
 
The histopathological findings in gastrointestinal tract include degeneration and necrosis of 
labial mucosa, mucosal and submucosal congestion, degeneration and necrosis of intestinal 
epithelium and lymphoid cell depletion in Peyer’s patches. Mucosal alterations are 
surrounded by a mild inflammatory infiltration of macrophages and lymphocytes at the 
borders of the lesions [133]. There is lymphocytolysis and occasional syncytia formation in 
lymphoid tissues. The viral antigen can be found in conjunctival, tracheal, bronchial, 
bronchiolar and ileal epithelial cells. It is also found in pneumocytes, macrophages, and 
lymphoid and reticular cells in the lymphoid organs [106]. The viral antigen is mostly found 
on the apical portions of the proliferating surface epithelium on the luminal side [134]. 
 
2.5 Clinical signs 
The length and severity of disease may vary according to species or breed involved, along 
with age and immune status of the animal. The PPR clinical description [54, 135, 136] can be 
divided in four forms, i.e., peracute, acute, subacute, and subclinical.  
 
The peracute form is seen when PPR occurs in young and naive populations of sheep and 
goats. It starts after an incubation period of about 1 to 3 days and is clinically characterized by 
high fever (40-42°C), dullness, anorexia, and constipation. There is congestion of oral and 
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ocular mucosa initially, however, after two to three days of pyrexia, occulo-nasal discharges 
are observed and oral mucus membranes are occasionally eroded. The affected animals 
develop profuse watery diarrhea and die within 4 to 6 days after onset of hyperthermia. 
 
The acute form is the most frequent. The first symptoms arrive after 3-4 days of incubation 
and include sudden hyperthermia and mucosal congestion. Diarrhea starts 2-3 days after the 
onset of fever. Animals become depressed, anorexic, dehydrated and have serous occulo-nasal 
discharges (which may later become muco-purulent). The epithelial lesions are mostly found 
on lips, gums, dental plate, tongue, and also on labial surface of vulva in female animals. 
Pregnant animals may abort. There are signs of bronchopneumonia with occasional 
productive cough. The muco-purulent discharges in later stage may be followed by crusting of 
nares, causing sneezing and coughing. Finally, there is hypothermia, prostration, and death 
may occur 10-12 days after onset of fever, some animals may survive for three weeks. 
Mortality rate may reach 70-80%. 
 
The subacute form of the disease is seen after about one week of incubation period and is 
clinically characterized by a low grade fever and either less severity or absence of other 
clinical signs. Many animals will recover after about 10-14 days of illness.  
 
In the subclinical infection, no clinical signs appear and can only be diagnosed serologically.  
The clinical picture may change during course of infection by complication due to secondary 
bacterial infections of oral, intestinal and respiratory tracts. Furthermore, PPR is characterized 
by immuno-depression, and this may activate latent intestinal or blood parasites [133].   
(a)                                                                    (b) 
 
      
 
 
 
 
 
 
 
 
 
Figure 8: (a) Oral lesions and (b) nasal discharge caused by PPRV infection in goats (Source: 
Abdallah Traore, LNRV, Bamako, Mali) 
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2.6 Diagnosis  
PPR can be diagnosed on the basis of clinical signs, as well as laboratory tests. The clinical 
diagnosis is based upon major clinical signs of PPR like which include fever, oral erosive 
lesions, dyspnoea, and diarrhoea. However, definitive diagnosis is possible only with 
laboratory tests. 
 
2.6.1 Differential diagnosis 
Certain clinical signs manifested in PPR in small ruminants can also be found in some other 
infectious diseases of sheep and goats.  
- Rinderpest: PPR has long been confused with rinderpest however unlike PPR there 
no respiratory problems associated with RP. Moreover, RP is almost eradicated now. 
- Pasteurellosis: It does not have involvement of digestive system, however may exist 
as a secondary infection alongside PPR. 
- Contagious ecthyma: similar to subacute form of PPR, however the lesions are not 
erosive but are in the form of papules or pustules which sometimes be found on mouth 
and nose.  
- Foot and Mouth Disease: Oral lesions are present but there is absence of respiratory 
problems and diarrhoea 
- Bluetongue: affects mainly the sheep but rarely the goats and is characterized by signs 
of congestion of oral and nasal congestion and edema of lips and tongue there is 
oedema of the face which are not found in PPR. 
- Contagious Caprine Pleuropneumonia: is not characterized by diarrhea or oral 
erosive lesions. 
 
In case of suspicion, the confirmatory diagnosis can only be based on laboratory tests. The 
samples can be collected either from the living sick or freshly died animals. Blood samples 
with and without anticoagulant should be taken for obtaining infected peripheral blood 
mononuclear cells (PBMC) and serology, respectively. Swabs or nasal and ocular discharges 
should be taken. Tissue samples should also be taken from thymus, mesenteric and bronchial 
lymph nodes, lung and intestines. The samples must be rapidly transported at 4°C to 
laboratory for diagnosis. For rapid sample collection, blood or nasal and ocular discharges can 
also be sampled on filter papers, dried and stored over long periods (up to 9 months) at 
ambient temperatures [137].  
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The laboratory tests for diagnosis of PPR are based upon isolation of virus, detection of viral 
genome, and detection of viral antigen or antibodies. Virus isolation is the classical technique 
for diagnosis and still serves as a gold standard. In past, primary kidney or lung cells of goat 
or Vero cell (kidney cells of African green monkey) cultures were used, which required 
numerous blind passages and the isolation was often not efficient [138]. However, since 
discovery of the fact that SLAM is the common receptor of morbilliviruses [139], 
Vero.DogSLAMtag (expressing canine SLAM receptor) [140] and CV1 cell line (expressing 
sheep SLAM receptor) [141] have been developed in recent years, which have improved 
PPRV isolation in vitro. Cytopathic effects (CPE) induced by the virus in these cells can be 
observed much earlier, in fact within two days after infection instead of 2-3 weeks for the 
normal vero cells [141]. However, for virus isolation good quality and well conserved 
samples are still required.  
 
Various diagnostic tests are available which are based upon detection of viral antigens like 
agar gel immunodiffusion (AGID), and immunocapture ELISA (Enzyme-linked 
Immunosorbent Assay [142]. While for viral antibody detection tests like virus neutralization 
test (VN), indirect ELISA and competitive ELISA are used [143]. Among these test, AGID is 
incapable of discriminating between PPR and RP but immunocapture ELISA based 
monoclonal antibodies [144, 145] against PPRV or RPV can efficiently discriminate between 
the two viruses and have proven to be rapid, sensitive and specific tests (115). Numerous 
diagnostic tests which use nucleic acid based detection of the pathogen which includes use of 
radioactive or non-radioactive DNA probes, conventional reverse transcription-PCR (RT-
PCR), quantitative RT-PCR (QRT-PCR) [142, 146]. PCR based diagnostic tests are highly 
specific and, using specific primers, can not only discriminate between PPRV and RPV, but 
are also capable of discriminating between lineages of PPRV. 
 
2.7 Prophylaxis and treatment 
To prevent the spread of PPR to new areas, measures like controlling the movement of 
animals from the areas endemic for PPRV is of primary importance. However, in case of an 
outbreak of the disease in a new area, the most effective solution would be to kill the infected 
animals and destroy the cadavers [36]. However, PPR is endemic in developing countries 
therefore stamping-out policy is seldom accepted due to high costs. The only viable 
prophylactic measure is vaccination of the susceptible animals around the affected area. 
Effective vaccines are available against PPRV since long time. Rinderpest vaccine, being 
cross protective against PPRV, was used initially but it can no longer be used due to Global 
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Rinderpest Eradication Program. Indeed, rinderpest vaccination was banned in the process of 
eradication to allow effective epidemio-surveillance of the circulation of any residual virus 
and avoid confusion between infected and vaccinated animals using the available antibody 
detection tests. An effective homologous vaccine is available since 1989 [147], which 
provides immunity against the disease during the economic life of small ruminants.  
 
There is no effective treatment against PPR, once animals are infected. The sick animals can 
only be provided supportive and symptomatic therapy. Antibiotics are also given to prevent 
secondary bacterial infections. Not much research has been done for discovery of antiviral 
agents effective against PPRV. As for as small molecular drugs are concerned, there is only 
one report of in vitro testing of a synthetic compound 4,4′-(arylmethylene)bis(1H-pyrazol-5-
ols) for its ability to inhibit CPE produced by PPRV and this compound was found to be more 
potent than the standard drug ribavirin [148]. The in vivo use of classical small molecular 
antiviral drugs has serious limitations due to toxic side effects and emergence of resistant 
strains [149]. The antivirals based RNA interference (RNAi) are a promising approach as they 
are highly specific end effective in their action. However, even after more than a decade after 
their discovery, their development as a therapeutic tool is hindered by problems of in vivo 
delivery. In fact, problems are somewhat similar as the gene therapy has been facing since 
1980s.  
 
3.  Interfering RNAs as antivirals and their delivery vectors 
 
3.1 RNAi 
RNAi is a highly specific, evolutionarily conserved, post transcriptional gene silencing 
mechanism used by cells for gene regulation, protection of genome against transposable 
elements and the attack of RNA viruses. While RNAi plays an important innate antiviral 
defense mechanism in plants and insects [150, 151], whether RNAi as antiviral immune 
mechanism really exists in mammals, remains unclear [152, 153]. However, the enzymatic 
machinery for RNAi is used by the other endogenous non-coding small RNAs like 
microRNAs (miRNAs), for regulation of gene expression [154, 155]. It is estimated that 
RNAi mediated gene regulation controls the expression of about 30% of mammalian genes, 
many of which are involved in functions like cell fate, proliferation and death [156]. 
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3.1.1 Discovery 
The phenomenon of RNAi was first observed by Napoli et al in 1990, when they were trying 
to over express an enzyme responsible for plant coloration by introduction of the exogenous 
gene in petunias [157]. Surprisingly, the introduced gene resulted in a blockage of pigment 
synthesis. The phenomenon of gene suppression, however, was not understood at that time. It 
was Andrew Fire and Craig Mello who finally established the mechanism in 1998, by 
demonstrating that injection of short stretches of 23mer to 25mer nucleotide sequence of 
double stranded RNA (dsRNA) into the nematode Caenorhabditis elegans resulted in 
silencing of endogenous genes [158].  Fire and Mello were awarded the Nobel Prize for 
Medicine or Physiology in 2006 for their discovery. This mode of gene silencing was 
different from the already established anti-sense mode of gene silencing in that, although both 
are based upon sequence complementarity to messenger RNA (mRNA). RNAi has a catalytic 
component that makes it possible for a single small interfering RNA (siRNA) molecule to 
bind with and destroy thousands of copies of mRNA molecules and thus is 1000 times more 
effective than antisense oligonucleotides (ODNs) in silencing target gene [159-161].  
Subsequently, it was reported that RNAi could take place in numerous other organisms 
including invertebrates, and vertebrates [125, 126]. Elbashir et al in 2001, showed that 
transfection of synthetic siRNAs could silence genes in mammalian cells [127]. Since then 
RNAi has found widespread applications ranging from use in functional genomics and gene 
knock-down, to treatment of various medical conditions like macular degeneration, cancers 
and viral infections. 
 
3.1.2 Mechanism 
RNAi machinery in mammals is used by miRNAs for regulation of gene expression. The 
miRNAs are transcribed by polymerase II as long primary transcripts or pri-miRNAs [162]. 
The pri-miRNAs undergo a sequential maturation process in which they first bind to a 
microprocessor, a complex of two proteins in the nucleus which contains the DiGeorge 
Syndrome critical region-8 (DGCR8) protein and a nuclear RNase III called Drosha [163-
165]. Next the Drosha cleaves pri-miRNAs into pre-miRNAs, which are the imperfectly 
paired stem-loop miRNA precursors having 60 to 80 nucleotides. The pre-miRNAs are then 
exported to the cytoplasm by Ran GTP-dependent Exporting-5 transporter [166, 167]. The 
Dicer (an RNase III family enzyme) at first, interacts with its double stranded RNA-binding 
protein partner (TAR RNA binding protein; TRBP) and other partners to cleave pre-miRNAs 
into mature double-stranded miRNAs of 19-25 bp with 2 nucleotide 3’ overhangs [168]. 
Then, Dicer together with R2D2 protein and its partners, couple with miRNAs duplex to form  
 51  
RISC loading complex (RLC), which helps in the loading of the miRNA duplex into another 
multiprotein complex, having Argonaute protein as its core component. This new complex is 
called RNA-induced silencing complex (RISC or miRNA protein complex (miRNP)) [155, 
169, 170]. After attachment to RISC, the passenger strand of miRNA is lost, while antisense 
strand guides RISC to the target mRNA. The miRNAs pair perfectly or imperfectly with the 
target mRNAs and thus may either result in endonuclease Argonaute 2 mediated cleavage and 
destruction of guide strand-mRNA duplex or blockage ribosome movement halting mRNA 
translation, respectively [171].  
 
Figure 9:  Mechanism of RNA interference (Schematic representation - according to Keck, 
2008) [172]  
 
The degree of miRNA-mRNA complementarity has been considered to be the key 
determinant of the regulatory mechanism. Thus, in case of a perfect match, mRNA is cleaved 
by RISC, while central mismatches may result in repression of mRNA translation [154].  The 
plasmid or viral vector expressed short hairpin RNAs (shRNAs) and chemically synthesized 
siRNAs mimic mammalian pre-miRNAs and miRNAs respectively and thus use cellular 
machinery for gene silencing. The only difference being that, the antisense strand of siRNA, 
acting as a guiding strand pairs perfectly with the target mRNA resulting in RISC-mediated 
cleavage of the target mRNA [173]. Viral/plasmid vector based shRNAs, transcribed from a 
polymerase III promoter, are produced in the nucleus and exported to the cytoplasm by 
exportin-5 together with GTP-bound form of its cofactor Ran, and are processed by Dicer like 
pre-microRNAs to produce siRNAs [167].  
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3.1.3 Interfering RNAs as an antiviral therapeutics 
The infection by negative sense RNA viruses requires the transfer of viral genome into the 
host cells, transcription of the viral mRNA, and translation of the viral proteins that are 
needed for viral genome replication, assembly, and budding. Targeting viral mRNA with 
siRNA is an attractive strategy since firstly, one can prevent synthesis of critical viral proteins 
to disrupt viral life cycle, secondly with siRNAs, being highly specific, there is little chance 
of side effects, and finally, understanding of gene function is not required: only viral genome 
sequences are needed [174].  Soon after discovery of RNAi, its potential as effective antiviral 
therapy was recognized. RNAi antiviral treatment was first used by Bitko and Barik in 2001 
against respiratory syncytial virus (RSV) [175]. Since then the approach has been variously 
exploited for antiviral purposes, not only through the use of chemically synthesized siRNAs 
but also by expressing the shRNAs from plasmid or viral vectors [176-178]. RNAi through 
these various approaches could effectively block viral replication in vitro but for in vivo use, 
delivery issue is still a major hurdle.    
 
 
3.1.4 Difficulties in use of RNAi as an antiviral approach 
The therapeutic use of RNAi in vivo faces other practical difficulties than those related with 
delivery, like off-target effects, RNAi suppression and viral escape. 
 
3.1.4.1 Off-target effects: 
Although RNAi is highly specific, in addition to the intended mRNA suppression, it also 
produces unintended effects on gene expression. For in vivo delivery, off-target effects are 
major concerns since the down-regulation of self genes could have serious biological 
consequences. They may result from either a partial sequence complimentarity of RNAi 
construct to non-targeted mRNA or induction of a variety of immune and toxicity related 
effects emanating from certain motifs or patterns in the RNAi construct itself  [179]. 
 
3.1.4.1.1 Specific off-target effects dependent on siRNA sequences 
Although initially thought to be highly specific, RNAi was shown by expression profiling to 
produce off-target effects whereby a particular siRNA will bind to other mRNAs than the one 
originally targeted. Partial sequence complementarity in both the passenger or guide strands 
of RNAi construct can produce off-target gene suppression [180]. The off-target silencing has 
been reported for transcripts with as low as 7 nucleotides complementarity with the guide 
strand [146].  siRNAs like miRNAs can also bind to sequences with partial complementarity 
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at the 3’-UTR rather than overall homology between the siRNA and targets [181-183].  
Furthermore, both the siRNA and shRNA with a complementarity in the “seed region”  
can produce similar off-target expression profiles [184], however shRNA is reported to 
induce fewer off target effects than siRNA [185].  
 
 
 
 
 
 
 
 
Figure 10: Seed dependant off-target effect. The capability of siRNAs to induce seed-
dependent off-target effect is highly correlated to the thermodynamic stability of the duplex 
formed between the seed region of siRNA guide strand and its target mRNA [186, 187]. 
 
 
3.1.4.1.2 Non-specific off-target effects - Induction of type 1 interferon (IFN) and 
other immune responses 
The animal immune system can discriminate between self and non-self nucleic acids. The 
double-stranded RNA (dsRNAs) longer than 30 bases can induce an immune response via 
protein kinase R (PKR), resulting in a general degradation of mRNA and inhibition of 
translation as well as up regulation of interferon (IFN) stimulated gene expression [188]. 
Moreover, even the smaller (<30 nucleotides) siRNAs, although initially considered non-
immunogenic [173], have been found to induce a partial cytokine and type-1 IFN response via 
toll like receptors (TLRs) [189-191]. It is also reported that although RNA sensing receptors 
are also found in the cytoplasm, nucleic acids mediate immunoactivation mainly through 
TLRs 7 and 8 (activated by ssRNA), TLR9 (by unmethylated CpG motifs in bacterial 
plasmids) and TLR3 (via dsRNA) [192-196]. siRNA immune stimulation via TLR7 and 
TLR8 on endosomes can be sequence dependent and therefore is possibly avoidable [191, 
193, 197]. The chemically synthesized siRNAs delivered by transfectants enter cells through 
endocytosis and are therefore more prone to cause immune stimulation via TLRs 7/8 found on 
endosomes. Conversely, shRNAs expressed intracellularly by plasmid and viral vectors, 
follow more closely the endogenous RNAi pathways and thus prevent interferon response 
[179, 198]. 
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3.1.4.2 Saturation of endogenous RNAi pathway components 
The enzymatic machinery involved in RNAi in mammalian cells is naturally used by miRNAs 
which play an important role in cell physiology. Since miRNA and shRNA share common 
enzymatic pathway for their processing, the over-expression of shRNA in vivo is known to 
produce toxicity due to over-saturation of endogenous miRNA pathway involving exportin-5 
and RISC component Argonaute-2 [199]. However, in vivo toxicity can be alleviated by the 
selection of efficient but safe shRNA expression cassettes, and applying minimal effective  
vector doses [199]. 
 
3.1.4.3 Viral encoded suppressors of RNAi  
Several plants and invertebrates use RNAi as an immune mechanism to counter viral 
infections [150, 151]. Therefore, viruses infecting these plants and insects have evolved their 
countermeasures by producing various suppressors of RNAi silencing (SRS) [200, 201].  
Some recent studies suggest that RNAi in mammals is also involved in antiviral responses and 
cellular regulatory miRNAs have a function in restricting virus replication in the cells [152]. 
Moreover, several mammalian viruses like hepatitis C virus (HCV), influenza virus, ebola 
virus, human immunodeficiency virus (HIV), vaccinia virus, and adenoviruses type 2 and 5 
are known to produce SRS factors that inhibit the RNAi mechanism. Many of these factors 
are multifunctional proteins which are known to inhibit interferon response as well [152, 
153]. Since the viruses producing SRS can be efficiently inhibited by RNAi, it appears that 
viral-suppression activity does not pose a serious difficulty for therapeutic RNAi [202]. None 
of the viruses belonging to the morbillivirus genus is reported to produce RNAi suppression 
through SRS factors. 
 
3.1.4.4 Viral escape 
Several applications of a single siRNA can lead to the emergence of viral escape mutants due 
to mutations in the target sites making viral genomes resistant to RNAi  [203]. Since, unlike 
eukaryotic DNA polymerase, RNA viruses lack proofreading activity, they tend to have a 
high error rate during replication which facilitates development of viral mutants [204]. After 
discovery of RNAi, an early study by Jacque et al., 2002, showed that even a single 
nucleotide mismatch in the siRNA target region may be sufficient to reduce the silencing 
effect of an siRNA on HIV-1 [205]. Interestingly, viral escape to RNAi can also occur by a 
point mutation outside the target sequence of siRNA, if this mutation changes local RNA 
folding into a structure that reduces the accessibility of the target sequence [206]. Several 
viruses have been reported to escape suppression by effective siRNAs, which include HIV-1, 
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HCV, HAV, and Poliovirus [207-210].  Studies of HIV-1 and HBV populations have shown 
that many resistant mutants may pre-exist before they have been exposed to inhibitors and the 
siRNAs may also exert selection pressure on these pre-existing resistant mutants [211, 212].  
The problem of RNAi escape can be more severe in chronic diseases as these require an 
extended antiviral therapy but may be less crucial in treatment of acute diseases [202]. 
However, design and selection of siRNAs targeting conserved regions of virus and 
combination of siRNAs targeting multiple genes or regions in viral genome can help avoid 
problem of resistance to siRNA therapy [213]. In a study using a T cell line expressing three 
potent shRNAs against HIV-1, it was found that even after an extended culturing for more 
than 100 days there was no viral replication [214]. A combination of four shRNAs that target 
different sequences of HBV genome has entered a phase I clinical trial [215]. However, use of 
multiple siRNA/shRNA doses must be optimized before use as some studies have shown that 
it is possible to saturate the RNAi pathway with high levels of shRNA expression [199]. 
Another possible alternative to targeting multiple conserved viral genomic regions is to use 
siRNAs that recognize the mutated target sites through use of siRNAs or shRNAs that target 
the most likely escape variants [216].  In vitro studies are needed to study the frequency of 
emergence of PPRV escape mutants and the viral sequences that are likely to mutate in the 
course of therapy. Since viruses tend to mutate, an alternative means could be to down-
regulate cellular factors which are required by the virus to either enter a cell or to replicate.  
 
3.2 In vivo delivery of interfering RNAs 
Compared to the large number of studies using siRNAs in cell culture, there have been 
relatively few studies in vivo. The progress is slower due to difficulties in delivery, especially 
by systemic route of administration [217]. The issue of drug delivery is not unique to RNAi 
based therapeutics, but here it is a major obstacle as the drug cargo (siRNA) is nuclease 
sensitive, has a net negative charge, and is hydrophilic, thus making difficult to keep it stable 
in serum and capable to cross the anionic and hydrophobic plasma membranes [218-220]. 
Moreover, for diseases like PPR, systemic delivery of siRNA is a necessity. In order to use 
RNAi as an antiviral approach, the siRNAs can either be chemically synthesized [175] or 
shRNA expression cassettes with Poll III promoters can be inserted into plasmid [176] or viral 
vectors [177, 221]. The viral vectors can efficiently use their own machinery to reach the 
target cells, transfer their genome into the cells and express shRNA molecules. 
The naked siRNAs and plasmid vectors, however, can not readily cross the cell membrane 
and therefore need delivery vehicles to help them to enter the cell cytoplasm. Bitko and 
colleagues successfully delivered naked siRNAs intranasally in a mouse model against 
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respiratory syncitial virus [19]. Interestingly, they compared delivery of siRNA with and 
without a transfection reagent, and noted only a marginal enhancement (20%) in the 
knockdown of the respiratory syncytial virus (RSV) target gene when lipid agent was used. 
However, the mechanism by which these cells take up these siRNA molecules remains 
unknown [222]. The systemic delivery route, however, is more difficult to approach. The 
unmodified siRNA has a half-life of less than an hour in human plasma and the siRNA 
molecules circulating in blood, are rapidly excreted by kidneys due to their small size [223]. 
The vectors are therefore needed not only to improve the bio-availability of siRNAs but also 
to provide protection from nucleases and help in penetration of anionic plasma membranes 
[224, 225] 
 
3.2.1 Physical methods of siRNA delivery 
The physical methods for in vivo delivery of siRNA involve mainly electroporation and 
hydrodynamic injection. The hydrodynamic injection involves a quick injection of siRNA or 
plasmid DNA (pDNA) in a large volume of physiological buffer, around one-tenth the mass 
of the animal, within a few seconds in the tail vein of the animal and this results in a delivery 
mainly to the liver [226, 227]. The early attempts for systemic delivery of siRNAs in vivo 
used the hydrodynamic injection method that was already tested by Liu et al., for pDNA 
delivery in mice [228]. McCaffrey et al., in 2002, in their studies on in vivo siRNA delivery 
by hydrodynamic method, demonstrated that co-injection of luciferase expressing plasmid 
with siRNA targeting luciferase produced efficient silencing of luciferase expression in the 
mouse liver [229]. Various studies using this method could deliver naked siRNA to 
hepatocytes, demonstrating functional knockdown of specific genes in the livers of mice 
[229-231]. Most studies are using hydrodynamic method for delivery of siRNA to liver as it 
can be much more easily transfected by this method as compared to other organs. This 
procedure is not clinically viable because of  potential damage to liver, as well as due to 
danger of volume overload side effects like right sided heart failure [232].  Moreover, it 
would be very difficult to scale up this method for use in large animals.  
 
The electroporation involves administration of an electric current for short duration, which 
temporarily increases the permeability of cell membranes, and thus allowing for passing of 
nucleic acids through membranes. The electric field polarizes the membrane molecules and 
temporarily destabilizes the membrane integrity, which results in greater permeability for the 
exogenous materials [233]. This technique has been successfully used to transfer siRNAs 
locally [234], but it cannot be used for systemic administration. Similarly, ultrasound is also 
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used for nucleic acid delivery [235]. These physical methods of delivery of siRNAs either 
cannot be used systemically or are too dangerous for clinical use.   
 
3.2.2 Chemical vectors for delivery 
The development of chemical vectors for siRNA delivery has been influenced by the studies 
on intracellular DNA delivery [236]. However, there are important differences between 
delivery of siRNA and DNA: i) size and charge of siRNA are lower than those of DNA; ii) 
cytosol is the place of action for siRNA while DNA has to enter nucleus to be effective [237]. 
The chemical methods of siRNA delivery involve formulation of negatively charged siRNA 
molecules with various polycations, like cationic lipids, peptides, polymers, or inorganic 
nano-structured materials, either through electrostatic or ionic interactions, with the aim of 
enhancing pharmacokinetic behavior, nuclease resistance, cellular uptake, target specificity 
and safety [18]. The general principle is based on complex formation between anionic siRNA 
molecules and cationic polymers resulting in complexes with net positive charge for 
facilitating interaction with anionic cell membranes. Moreover, the physico-chemical 
properties of the complexes like size, morphology, surface charge and stability, are the major 
determinants of transfection efficiency which in turn are determined by structure of 
polycation, the polycation/nucleic acid stochiometry (+/- charge ratio), pH and order of 
mixing of nucleic acids and the vectors [238].  Though most delivery vectors are cationic, the 
net surface charge of the vector-siRNA complex, has to be near neutral to avoid toxicity, 
excessive uptake by reticulo-endothelial system (RES) and aggregation by serum proteins [18, 
239]. In order to deliver siRNA cargo into target cell cytoplasm, the formulation has to 
surpass various physiological barriers (Fig. 11) by shielding siRNA from serum nucleases, 
avoiding aggregation by anionic serum proteins, escaping from RES, penetrating 
endothelium, getting internalized through endocytosis, and finally being able to deliver 
siRNA from the endosomes to the cytoplasm before degradation by lysosomes [18, 239]. The 
in vivo use of siRNA  by chemical delivery systems is limited by siRNA packaging 
efficiency, colloidal stability of the complex, internalization, and endosomal escape [240].  
 
 58  
 
 
Figure 11: Main physiological barriers to in vivo delivery of siRNA (Schematic 
representation according to Misra et al., 2010) [18] 
 
The chemical vectors used for siRNA delivery can be broadly divided into three major 
groups: lipids, cationic polymers, and peptides. 
 
3.2.2.1  Lipids as nucleic acid delivery vectors  
Bangham et al., (1965), while studying cell membranes, observed that phospholipids which 
are a major component of cell membranes, tend to form spontaneous spherical structures 
called liposomes upon contact with water [241]. Latter, Felgner et al., (1987), first brought 
demonstration of effective use of liposomes for in vitro transfection of DNA [242]. These 
liposomes were based on a cationic lipid called  DOTMA (N-[1-(2,3,-dioleyloxy)propyl]-
N,N,N-trimethylammonium chloride) [242]. Since then, many natural as well as synthetic 
cationic lipids have been developed and used for delivery of nucleic acids including DNA, 
antisense oligonucleotides and siRNAs. The preparation of these new cationic lipids involved 
either modification of the nature of cationic lipids [243], fatty acid side chains [244], or 
Vascular 
endothelial 
barrier  
 59  
formulations with some additional lipids [245]. Despite initial difficulties found in in vivo 
transfection, the death of a human patient participating in gene therapy trials based on an 
adenoviral vector in 1999 [246] and the resulting temporary ban on use of viral vectors for 
gene therapy by US Food and Drug Administration [247], lead to a renewed interest in 
chemical vectors.  
 
Typically, the cationic lipid molecules are amphiphilic or amphipathic in nature and are made 
up of three parts: a cationic head-group, a hydrophobic anchor, and a linker (Fig. 12b). The 
cationic head-group is required for binding and complexation of nucleic phosphate groups, 
whereas hydrophobic part probably assists in assembling the lipids into polycationic scaffold 
and facilitating absorptive endocytosis or fusion with plasma membranes [248]. The cationic 
lipids are classified on the basis of number of positive charges, nature of linker bond, and 
nature of hydrophobic anchor [248]. Although cationic lipids are the most common lipids 
used for liposome based transfections, often neutral and/or anionic lipids are mixed with these 
in variable ratios to neutralize excessive cationic charge and to improve endosomal escape 
[249]. The anionic lipids when added to nucleic acid-cationic liposome complexes, not only 
reduce cellular toxicity but also reduce nonspecific interaction with anionic serum proteins 
like albumin as well as extracellular matrix [250, 251]. Mastrobattista et al. (2001) were able 
to improve transfection by preparing positively charged polyplexes coated with an anionic 
lipid [251].  
 
The neutral lipids play a role of a helper when formulated with cationic lipids for preparation 
of liposomes. There are three neutral lipids which are often incorporated in the formulations: 
dioleyl phosphatidylethanolamine (DOPE), cholesterol and dioleoyl phosphatidyl choline 
(DOPC). The DOPE is known to destabilize lipid bilayers and is believed to be involved in 
endosomal disruption and thus enabling nucleic acids to escape endosomes before being 
destroyed by lysosomes [252]. Cholesterol is also used as a helper lipid. Although it forms 
more stable but less efficient complexes with nucleic acids than those containing DOPE in 
vitro, cholesterol containing lipoplexes show higher biological activity due to greater cell 
uptake and stability in serum, compared to lipoplexes with DOPE when these complexes are 
utilized in vivo [248]. The liposome mediated transfection has been shown to take place 
mostly by endocytosis [236]. However, probably a minor pathway mediated by fusion 
between siRNA containing lipoplexes and the plasma membrane is responsible for around 5% 
of siRNA delivery in to cell cytoplasm [236].  
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3.2.2.1.1 Cationic liposomes  
Liposomes are vesicles composed of a phospholipid bilayers with an aqueous core [253]. 
They are classified according to their size and their number of bilayers: Small Unilamellar 
Vesicles (SUV), Large Unilamellar Vesicles (LUV), Multilamellar Vesicles (MLV), and 
Giant Unilamellar Vesicles (GUV) (Fig. 12b) [254]. The complex formation between anionic 
phosphate group from nucleic acids and cationic amine head group of cationic liposomes 
results in formation of lipoplexes, which are quite different from liposomes in structure as the 
final charge as well particle size changes and these changes are determined largely by lipid / 
nucleic acid (+ / -) ratios [255].  
 
 
 a           b 
 
 
 
c 
 
 
 
 
 
 
Figure 12:  Structure of a cationic liposome. (a) formed by phospholipids in an aqueous 
medium [256]; (b) Classification of liposomes according to size and number of bilayers [254]; 
(c) Representative structure of cationic lipid DOTMA modified [257]  
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3.2.2.1.2 Liposome preparation 
The liposomes can be prepared by numerous methods, however the basic principle of their 
formation involves hydrophilic/hydrophobic interactions between lipid-lipid and lipid-water 
molecules [258]. Moreover, there is always a need for energy input (sonication, 
homogenisation, shaking, etc) which promotes the arrangement of lipid molecules in bilayers 
and achieves a thermodynamic equilibrium in the aqueous phase [258]. The classical method 
of liposome preparation used by Bangham et al. (1965), consists in evaporing the organic 
solvent into which lipids are dissolved, and then adding an aqueous solvent [241]. The 
hydration of lipid film causes phospholipids to self-associate so as to hide their hydrophobic 
chains to the aqueous solvent. It results in formation of bilayers enclosing the aqueous 
solvent. 
 
3.2.2.1.3 In vivo delivery of siRNA with liposomes 
DOTAP (N-[1-(2,3-dioleoyloxy)]-N-N-N trimethyl ammonium propane) and Oligofectamine 
were some of the first lipid formulations used for in vivo delivery of siRNA and effective 
gene silencing of TNF-alpha and beta-catenin in mice [259, 260]. Since then siRNAs have 
been successfully delivered locally but there are not many reports of successful systemic 
liposome based delivery of siRNAs against systemic viral infections. However, there are 
some studies showing promising results in terms of successful delivery of siRNAs and 
effective viral suppression in vivo by formulations based up on neutral lipids. For example, 
Morrissey et al. (2005) using three daily intravenous injections in mice of siRNA (3 
mg/kg/day) complexed with the neutral liposomes called “stable nucleic acid-lipid particles” 
(SNALPs) stabilized with PEG (polyethylene glycol) , could reduce serum DNA of  hepatitis 
B virus by more than 1.0 log10 and the effect lasted for up to 7 days after dosing [20]. In 
another experiment using intraperitoneal delivery of siRNAs complexed with SNALPs for 
seven days against Ebola virus has been shown to protect guinea pigs against viremia and 
death shortly after the virus challenge [261]. Using a lactosylated liposome based upon 
neutral lipid the phosphatidylcholine, Watanabe et al., (2007) could effectively deliver siRNA 
targeting hepatitis C virus (HCV) in a transgenic murine model, resulting in suppression of 
intrahepatic HCV expression without interferon response [21]. SNALPs developed by Protiva 
Biotherapeutics and Alnaylam, have also been successfully used to deliver siRNA in non 
human primates, whereby using a SNALP-formulated siRNA dose of 2.5 mg/kg, could 
markedly suppress the Apolipoprotein B (APOB) [262]. Despite encouraging results in 
murine models, there are no known reports of non-viral delivery of siRNAs in farm animals. 
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Systemic application of siRNA molecules by lipid based carriers is still challenging and 
issues of toxicity and need for targeted delivery still need to be addressed. 
 
3.2.2.2 Cell penetrating peptides (CPPs) 
CPPs or protein transduction domains (PTDs) are short peptides having fewer than 30 residue 
peptides, derived from natural or unnatural protein or chimeric sequences [263]. Most of the 
CPPs possess a high density basic amino acids (arginines and/or lysines), which are proposed 
to interact with the anionic surface of the cell membrane and enhance internalization of the 
peptides [264]. Among chemical delivery vectors CPPs are unique in that the concentrations 
of CPPs that are used for molecular delivery, produce very low or undetectable cytotoxicity 
[264].  
 
CPPs were first discovered when Frank and Pabo in 1988 observed that HIV-1 Trans-
Activator of Transcription (Tat) protein, which transactivates transcription of the HIV-1 
genome, crossed the cell membrane by itself [265]. Later, a minimal peptide fragment of Tat 
(49-59 amino acids) involved in cellular uptake was identified by a French group [266]). The 
Tat peptide has been shown to successfully deliver siRNAs in vitro [267]. Another major 
discovery in CPP domain was made by Joliot et al  (1991), who demonstrated that Drosophila 
Antennapedia home domain could be internalized by neuronal cells [268]. This work lead to 
discovery of the first CPP derived from a non-viral protein which consisted of a 16-mer 
peptide derived from the third helix of the Drosophila Antennapedia homeodomain protein 
and was named PenetratinTM [269]. The Penetratin is capable of transfecting nucleic acids 
antisense oligonucleotides [270], peptide nucleic acids (PNAs) [271]. A MPG peptide was 
used to perform the first non-covalent delivery of nucleic acids in 1997 [272]. The MPG 
peptide is an artificially constructed 27 amino acid amphipathic CPP containing a lysine rich 
basic region derived from the nuclear localization signal (NLS) of the SV40 large T antigen 
and a hydrophobic region derived from the HIV-gp41 coat protein [272]. Both the MPG 
peptide and a modified MPGΔNLS (having a single mutation of the second lysine residue in 
the NLS motif to serine) can transfect siRNA in vitro however latter is more efficient as it 
delivers siRNA into cytoplasm instead of nucleus [273]. MPG peptides have been also used to 
deliver siRNA into mice by systemic route [274]. Another milestone was achieved when a 
chimeric CPP “Transportan”, derived from the N-terminal fragment of the neuropeptide 
galanin linked to a wasp venom peptide called mastoparan was successfully used in vivo for 
delivery of peptide nucleic acids (PNAs), in mice [271]. The first CPP based transfection of 
siRNA was performed with a MPG peptide [275] and since then numerous natural and as well 
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as engineered CPPs have been tested for siRNA delivery [276]. Polyarginine-based peptides 
have also been successfully used for siRNA delivery. Majority of the CPPs possess basic 
amino acids (arginines and/or lysines), through which these interact with cell membranes and 
help in the internalization of CPPs [264]. The experiments on Tat and penetratin revealed that 
the role of positive charges is crucial for translocation [277]. After studying various cationic 
polypeptides, CPPs with polyarginines were found to be more efficient than other cationic 
polypeptides like polyhistidines and polylysines and among polyarginine peptides, Arg7 and 
Arg9 have been the most widely used for in vitro and in vivo delivery [277]. 
 
Although cellular uptake mechanism for CPPs has been reported to be associated with 
endosomal pathway [278], there is no unified mechanism established for CPP uptake 
mechanism up to now, and probably numerous factors are involved [263]. However, there is a 
consensus that the initial contact between the CPPs and the cell membrane take place by 
electrostatic interactions with negatively charged proteoglycans [263]. Moreover, as CPPs are 
diverse in chemical and physical structures, it is suggested that different properties like CPP 
molecule length, charge delocalization as well as size and charge of the cargo can have impact 
upon peptide uptake mechanism [279]. Cellular uptake of CPPs, therefore, does not occur by 
any single mechanism thus, energy independent direct diffusion, macropinocytosis, clathrin-
mediated endocytosis, and caveloe/lipid raft mediated endocytosis may all occur [280]. 
 
CPPs can be classified in two ways. These are classified either on the basis of mode of 
bonding with cargo into, those requiring covalent linkage with siRNAs and others which, 
being amphipathic, can form stable non-covalent bonds. Secondly, these can also be 
subdivided structurally into those which polycationic having clusters of polyarginine in the 
primary sequence or those which are amphipathic [263].    
 
 
3.2.2.2.1 Covalent attachment of CPP to siRNA 
Tat conjugated to the modified antisense strand of siRNA was successfully used to inhibit 
EGFP gene in vitro [281]. However, most of Tat-siRNA was found localized in endosomes 
and there was a concern that the attachment of Tat to siRNA may disrupt functionality of 
siRNA molecules [282]. To address this concern, CPPs have also been linked to siRNA 
through disulfide bond which is cleaved when conjugates reach reducing environment of 
cytosol, resulting in successful RNAi [283, 284]. The covalent strategy usually requires 
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complex chemistry for conjugation and there is also risk of alteration of biological activity of 
siRNA therefore non-covalent strategy of delivery appears more suitable [263]. 
 
3.2.2.2.2 Non-covalent CPP-siRNA complex formation 
Assembling siRNA/CPP complexes through non-covalent interactions is advantageous as it 
simplifies conjugation protocols but also eliminates the need for optimization of individual 
syntheses schemes. Additionally, there is also lower likelihood that CPP will interfere with 
the bioactivity of the cargo [263]. The non-covalent delivery of siRNA is based up on 
electrostatic interactions between siRNA and amphipathic peptides [264]. The amphipathic 
peptides possess hydrophobic (polar) and hydrophilic (non-polar) domains. The amphipathic 
property of CPPs may arise from either primary or secondary structure [277]. Primary 
amphipathic peptides consists of the sequential assembly of a domain of hydrophobic residues 
with a domain of hydrophilic residues while secondary amphipathic peptides are produced by 
conformational state that allows positioning of hydrophobic and hydrophilic residues on 
opposite sides of the molecule [277].  
 
Since siRNAs are negatively charged, they can bind with positively charged CPPs through 
nonspecific electrostatic interactions and provide permeability by covering the siRNA surface 
with positive charges from the CPP [264]. In 2003, a non-covalent strategy based on MPG 
was found to efficiently deliver siRNA into cell lines [285]. Similarly, this non-covalent mode 
of delivery has also been used for other CPPs like, Tat, polyarginine, and transportan-derived 
peptides [263]. A novel 20-amino acid amphipathic peptide, CADY, has been recently 
described which combines both cationic arginine and aromatic tryptophan residues into its 
design [286]. It forms stable complexes with siRNA through electrostatic interactions and 
interestingly uses a non-endocytic mechanism to pass through plasma membrane, thus 
avoiding endosomal entrapment [286]. This CPP can transfect a variety of cell lines, 
including difficult to transfect primary cell lines [286]. Since CADY-siRNA is stable in 50% 
serum for 24 hours and leads to significant knockdown with sub-nanomolar concentration, it 
may be effective in vivo as well [286]. 
 
3.2.2.2.3 In vivo delivery with CPPs 
CPPs have been delivered in vivo with some successes and failures. MPG peptide was used 
for systemic in vivo delivery of siRNA targeting essential cell cycle protein cyclin B1, 
resulting in efficient blockage of tumor growth [287]. In another experiment, siRNA targeting 
HIV was successfully delivered through a CD7-specific single-chain antibody conjugated to 
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the oligoarginine peptide (scFvCD7-9R) could effectively suppress HIV infection in a mouse 
model [22]. The CD7 receptor is rapidly internalized after antibody binding, therefore it has 
been exploited for the targeted delivery of several monoclonal antibody (mAb) [22]. Kumar et 
al., [27] using a nonamer arginine was introduced at the carboxy terminus of a peptide 
derived from rabies virus glycoprotein (RVG) were able to transfer siRNA into neuronal cells 
in vivo, resulting in efficient gene silencing after intravenous injection into mice. 
Furthermore, systemically delivering of RVGR9 conjugated antiviral siRNA complex could 
protect mice from encephalitis induced by Japanese encephalitis virus (JEV) infection, which 
is the first report on a nontoxic method to deliver siRNA across the blood brain barrier [288]. 
CPP based siRNA delivery has also entered at level of preclinical and clinical trials, with 
Traversa Inc., are testing HIV Tat-based and Panomics Inc., testing secondary amphipathic 
peptide-based non-covalent delivery of siRNA [263]. 
 
3.2.2.3 Other chemical vectors 
Aptamers are RNA or DNA oligonucleotides that fold by intramolecular interaction into 
unique three-dimensional conformations capable of binding to target antigens with high 
affinity and specificity [289]. The aptamers have been used as siRNA vectors in a mouse 
tumor xenograft model, however their systemic use requires addition of nuclease stabilizing 
agents and endosmolytic functionalities [18]. Dendrimers molecules are repeated branched 
species characterized by structural perfection [18]. Dendrimers have been used successfully 
for in vitro delivery of siRNAs [290].  Polyethyleneimines (PEI) are  polycation-containing 
block copolymers like [291], which have also been used for delivery of siRNA molecules in 
vivo, although PEI use in vivo has some toxicity issues [292]. Chitosan is a biodegradable, 
biocompatible and non-toxic cationic polymer obtained from deacetylation of chitin, which 
have been proposed as biocompatible alternative cationic polymers, suitable for nonviral 
nucleic acid delivery[293]. Chitosan have been used for siRNA delivery in vitro as well as in 
vivo [294]. Antibody-protamine fusion carriers have also been shown to be efficient in 
delivery of siRNA to HIV-infected or envelope-transfected leukocytes [295]. 
 
3.2.3 Viral vectors 
 
Like chemical vectors, the viral vector based delivery of shRNA also profited from 
technology that already existed for gene therapy. Soon after delivery of siRNAs in vitro [175], 
it was demonstrated that siRNAs can also be expressed from plasmid DNA as “short hairpin 
RNAs” (shRNAs) [296, 297]. This finding paved the way for viral vector based RNAi 
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therapeutics. U6 [297] and H1 [296] were the first polymerase III promoters described that 
express functional siRNAs [298]. However U6 promoters have been reported to be more 
efficient in vivo [299]. Typically, shRNA transcription starts in a position outside the 
promoter sequence, continues along 19-29 nucleotide long top strand, the 4-19 nucleotide 
long hairpin loop and finally the bottom strand and terminates after the second or third residue 
of track of 4-6 thymidines [298]. The termination is so designed that it results in a 3’ two- 
nucleotide overhang after RNAse III cleavage as is the case with natural pre-miRNAs [298]. 
The shRNA sequences are selected and translated to DNA, and these are normally 
synthesized in the form of two complimentary oligonucleotides that are annealed and cloned 
downstream of the selected promoter and regulatory sequences [298]. The constructed shuttle 
plasmids expressing shRNA are next tested for inhibition of target gene in vitro. Moreover, 
the cassettes may be inserted into expression clones for production of required recombinant 
virus vectors. In addition to standard shRNA resulting in production of a 21 nt long siRNAs, 
numerous other variations of shRNA have also been used. Longer shRNAs producing 27- 29 
nt long siRNAs [300, 301], and multiple shRNAs simultaneously expressing different 
shRNAs against different target regions have been used [302, 303]. The viral vectors have 
certain advantages over chemical vectors for delivery of siRNAs like [298];  
1. tissue specific delivery of shRNAs. 
2. possibility of inducible or tissue specific promoters. 
3. both transient as well as stable expression of shRNA is possible, according to the viral 
vector chosen. 
4. better transduction efficiency compared to non-viral transfections even in cells like 
lymphocytes that are traditionally hard to transduce. 
5. cost effectiveness. 
6. most of the available viral vectors have already been tested clinically in phase I safety 
trials. 
The most widely used viral vectors for shRNA delivery include adenovirus, adeno associated 
virus (AAV), lentivirus, retrovirus, baculovirus. In contrast to the gene therapy, shRNA 
expressing cassettes tend to be of small length and their expression is possible even by the 
smallest vectors [298]. However, viral vectors are selected on the basis of tissues required to 
be transduced and also whether stable or transient transduction is required. For chronic 
infections like HIV stable transduction is desirable to avoid repeated administration of vectors 
while for acute infections, transient transductions with shRNA expressing vectors would 
suffice. The RNA viruses such as retrovirus and lentivirus produce stable transduction as they 
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integrate into host genomes while non-integrating DNA viruses like adenovirus, baculovirus 
and AAV maintain their genome episomally in the host cells.  
 
3.2.3.1 Adenovirus vectors 
Adenoviruses (Ads) are non-enveloped viruses having a linear double stranded 36 kbp DNA 
genome with non-enveloped icosahedral protein capsid. Adenoviral capsids are made up of 
three major protein components – the hexon, penton base and fiber (Fig. 13) [304]. In general, 
the fiber knob functions as the major attachment site for cellular receptors, while the penton 
base is involved in secondary interactions that are required for virus entry into the cell [304]. 
More than 50 serotypes have been identified which are divided into six subgroups (A-F). Out 
of the numerous serotypes, Ad2 and Ad5 belonging to subgroup C were first shown to serve 
as efficient vectors gene delivery in vitro [305] and still are the most commonly used 
adenoviral vectors [306]. For gene therapy as well as for RNAi, replication defective 
adenoviruses can be used since they are non-pathogenic and can transiently transduced a 
variety of both dividing and non-dividing cells without integration to the host genome [298].  
 
Figure 13: Structure of Adenovirus [307]. 
 
In the past it has been considered that adenovirus serotypes belonging to species A, C, D, E 
and F use the coxsackie and adenovirus receptor (CAR) as a docking site providing a high 
affinity virus-to-host association [308].  CAR was previously thought to be a primary Ad5 
receptor, but now there are studies according to which adenovirus type 5 also uses many other 
receptors for docking like the heparan sulfate proteoglycan (HSPG), vascular cell adhesion 
molecule 1 (VCAM-1), major histocompatibility complex class I (MHC 1), scavenger 
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receptors (SR), while indirect binding it also uses dipalmitoyl phosphatidylcholine receptors 
(DPPCRs), coagulation factor X (FXs), and Lactoferrin receptors (LfRs) [309]. Although 
receptor binding is thought to play a major role in adenoviral tropism, this alone cannot 
explain all aspects of in vivo host-virus interactions like enhanced transductions of liver cells 
or adenoviral uptake by Kupffer cells [310]. Excessive adenoviral binding to hepatocytes may 
be partly explained by binding of central depression of adenoviral hexon with Gla domain of 
coagulation factor X (FX) which has been found to produce efficient transduction of 
hepatocytes [311]. That may explain excessive liver tropism of adenovirus where FX could be 
the main determinant of in vivo liver transduction [311]. 
 
The internalization of adenovirus occurs by a secondary interaction between RGD motifs on 
penton base protein and integrins αvβ3 and αvβ5 [312] through clathrin-coated pits mediated 
endocytosis [313]. The virus then escapes by lysing endosomal membrane and with the help 
of microtubule mediated translocation, enter the nuclear pore complex where viral DNA is 
released for expression [314]. The transcription of wild type virus initiates with expression of 
early E1 genes, which activate synthesis of viral genes and replication. E1 and the non-
essential E3 genes were deleted in first generation adenoviral vectors to render them 
replication deficient [298]. But these first-generation adenoviruses express viral genes to low 
levels, including virus associated (VA) RNAs which have been described to saturate the 
cellular silencing machinery, leading to toxicity [315]. Although functional inhibitory 
exogenous shRNAs have been expressed for first generation adenoviral vectors without 
saturation of silencing machinery [316]. The second generation vectors, which have deletions 
in the E1-E4 locus are comparatively less immunogenic and show prolonged expression of 
recombinant genes [317]. Whereas third generation adenoviruses are produced by deleting all 
the viral genes, as a result of which expression of viral genes is avoided resulting in lesser 
immunogenicity [318]. 
 
The recombinant replication deficient adenoviruses have been successfully used in vitro as 
shRNA delivery vectors against numerous viruses like hepatitis B virus [221], measles virus 
[319] and hepatitis C virus [320].  The adenoviral vectors expressing shRNA have been 
successfully used in vivo against several viral infections. After pre-treatment of  guinea pigs 
and swine with adenoviral vectors expressing shRNA against foot and mouth disease virus 
(FMDV), and challenging 24 hours later with the target virus, Chen et al., could protect the 
animals from major clinical manifestation of the disease [23]. Similarly adenoviral vectors 
have also been used to protect mice against porcine circovirus type 2 [225]. 
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3.2.3.2 Baculovirus vectors 
The baculoviruses belong to the family Baculoviridae which is subdivided into two genera: 
the granuloviruses (GV) and nucleopolyhedroviruses (NPV). The GV contain one 
nucleocapsid per envelop but the NPV may either contain single (SNPV) or multiple (MNPV) 
nucleocapsids for each envelop in the occlusion body [321]. Furthermore, the NPV capsids 
are occluded in polyhedron matrix and the polyhedra may contain multiple embedded virions 
[322]. Among the numerous baculoviruses, Autographa californica multiple 
nucleopolyhedrovirus (AcMNPV) is the most well studied and extensively used virus in 
foreign gene expression [323]. AcMNPV possesses a circular double stranded DNA genome 
which is condensed into a nucleocapsid core by a protamine-like protein. Naturally AcMNPV 
are occluded in a polyhedron which after being ingested by insects is dissolved in alkaline 
midgut, releasing infectious virions [323]. 
 
Figure 14: Structure of a Budded baculovirus. According to Blissard, 1996. [324] 
 
The AcMNPVs only replicate in insect cells and naturally infect insects belonging to the order 
Lepidoptera. Baculoviruses primarily enter insect cells through clathrin-mediated, low-pH 
dependent endocytic pathway while they may enter mammalian cells through multiple 
pathways including caveola-dependent mechanism as well [325]. However, AcMNPV can 
infect insect cells and transduce mammalian cells even in the absence of endocytosis, by 
direct fusion at cell surface under low pH conditions [326].  
 
The baculoviruses can enter the mammalian cells but they are unable to express their genes 
because the baculovirus promoters are inactive in these cells [327]. One of the interesting 
consequences of this is the absence of pre-existing antibodies against baculovirus in mammals 
[327, 328]. For gene transfer and expression in mammalian cells, so-called BacMam viruses 
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have been generated by incorporation of mammalian cell-active expression cassettes [329]. 
BacMam baculoviruses are capable of transducing wide variety of cells including non-
dividing cells [330] and primary cells [331]. They  have been used to reduce viral infections 
in vitro of numerous viruses like porcine arterivirus [332], hepatitis C virus [333], hepatitis B 
virus [334], and influenza viruses A and B [335].  
 
The baculovirus can prove to be good shRNA delivery vectors in vivo. Although delivery of 
siRNA to the appropriate cells or tissues is a major challenge, problem of inactivation by 
complement is resolved [336]. Chemical or genetic modification can also overcome problem 
of serum inactivation [337, 338]. Furthermore, it is reported that baculoviruses do not have 
deleterious effects on mammalian cells even when used at very high multiplicity of infections 
(MOIs) [339]. Moreover, not only can the baculoviruses be easy and cheap to produce, they 
can be grown to high titers in cell cultures as well. Although baculovirus vectors have not 
been used thus far for shRNA delivery in vivo, but these have been successfully used for gene 
transfer into mouse brain and rabbit retina [340, 341]. 
 
3.2.2.3 Other viral vectors 
Many other viral vectors have been used for RNAi mediated silencing of viral infections like 
adeno-associated virus (AAV) [342], herpes simplex virus [24], retroviruses [296], and 
lentiviruses [177]. Moreover, these viral vectors have also been used against infectious 
disease of veterinary importance. Infectious bursal disease virus (IBDV) by an avian adeno 
associated virus delivered miRNAs targeting VP1 and VP2 genes in vitro [343]. Recombinant 
herpesvirus of turkey (HVT) expressing shRNAs against genes gB and UL29 of the Marek’s 
disease virus (MDV) moderately reduced viremia in chicken [24]. In another study, avian 
leukosis virus-based retroviral vectors expressing shRNA against MDV gB glycoprotein gene 
and ICP4 transcriptional regulatory gene could significantly reduce MDV viremia in vivo 
[25]. 
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4. Control of Morbillivirus Replication by RNAi – State of the art 
 
RNA interference has become the method of choice for suppression of gene expression in 
vitro. The synthetic short interfering RNAs (siRNAs) represent a new class of molecules with 
a significant potential for therapeutic applications. This technology promises to bring benefits 
in this field that far surpass the antivirals currently available in the market, as it offers new 
possibilities to easily design highly selective antiviral drugs capable of targeting specific 
genes in order to suppress its expression and this with a very low toxicity as its natural 
nucleotide components are easily metabolized by cellular systems [344]. 
 
This method is now emerging as a powerful tool for research with many published studies 
using siRNA in mammalian cell culture. They show that synthetic siRNA are particularly 
effective in the areas of oncology and the treatment of viral infections. siRNAs have been 
widely used against viruses of various families to inhibit the intracellular viral life cycle. The 
first experiments carried out on an unsegmented, negative sense, RNA virus, the respiratory 
syncytial virus (RSV), go back to 2001 [175]. A publication by Reuter et al., [345], describes 
the generation of multiple siRNAs directed against 6 genes of a morbillivirus, measles virus 
(MV) can effectively deregulate gene expression in general with siRNAs against transcripts of 
the nucleocapsid (N), phosphoprotein (P) and polymerase (L), which form ribonucleoprotein 
(RNP) complex. Two other publications describe the use of siRNA to inhibit replication in 
cell culture of MV and subacute sclerosing panencephalitis (SSPE) virus [346, 347]. 
However, these studies show inhibition of measles replication only in vitro but siRNA against 
morbilliviruses have not been successfully delivered in vivo so far. 
 
In the case of morbilliviruses, despite existence of efficient vaccines against morbillivirus 
diseases, no effective treatments exist for infected animals or humans. RNA interference 
(RNAi) has a potential of being turned into an effective and specific antiviral therapy for the 
control of these diseases. In case of disease outbreaks, the emergency vaccination alone, in 
poor countries does not prevent heavy economic losses arising from animal mortality as well 
as morbidity. Moreover, even after administration, the vaccines require several days before a 
sufficiently strong protective immune response is present. Under these circumstances, an 
antiviral that can block viral replication in the early stages of infection could be an important 
complementary tool in the control strategy. A combination of antiviral agent together with 
vaccination may reduce the economic losses incurred during an epidemic.  
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The in vitro tests conducted by the CIRAD have helped in identification of three sites 
susceptible to RNAi, which are located on the conserved regions of nucleoprotein gene of the 
morbilliviruses, through an siRNA design methodology that allows the rapid prediction of 
potential sequences on target mRNAs [348]. These strategies for predicting design done on 
the conserved regions of the genome should lead to the use of lower doses of siRNA while 
reducing non-specific off-target effects. Indeed, knowledge of morbillivirus genomes allowed 
us to develop an antiviral approach based upon RNAi against these three morbilliviruses. 
Briefly, sixty two 19 nt long siRNA sequences targeting N, M, and F genes of three genes of 
peste des petits ruminants virus (PPRV), rinderpest virus (RPV) and MV were designed, 
chemically synthesized and tested for efficacy in vitro [348-350]. Three sequences directed 
against nucleoprotein (N) gene, namely NPPRV1, NPPRV6, and NPPRV7, were found to be 
most effective and resulted in reduction of viral titer to about 1,000 to 10,000 times and also 
an inhibition of up to 90% of the nucleoprotein expression by PPRV when transfected at a 
final concentration of 100 nM (Tab. 1).  
 
However, for systemic administration of siRNA in vivo to be successful, numerous 
constraints, as were described in the review of literature of this document, including poor 
transfection in vivo, which is also the major issue with other nucleic acid based strategies, a 
low serum stability and toxicity need to be overcome. Even after more than a decade of 
discovery of RNAi and despite excellent knock down of viral or cancer genes in vitro, its 
therapeutic application has not been possible due to these difficulties involved in the efficient 
in vivo delivery. Although some siRNA based therapeutics have entered clinical trials, these 
are mostly for local use only, whereas systemic delivery has proven to be a significant hurdle. 
Since PPR is an acute and systemic infection of small ruminants, transient transfection or 
transduction are required for systemic delivery of siRNA/shRNA in vivo. For that purpose, in 
this work several chemical delivery vehicles as well as viral vectors were considered for their 
ability to deliver the siRNA NPPRV1 directed against the nucleoprotein gene of PPRV, 
previously selected as the most effective in inhibiting PPRV replication after delivery by a 
commercial liposome in cell cultures. 
 
A process of reflection by the laboratory, on the selection and development of delivery 
vehicles was crucial for the success of in vivo studies. Indeed, due to their intrinsic 
mechanisms, the viruses prove efficient delivery vectors, while despite certain drawbacks like 
toxicity, the cationic lipids are also delivery systems of choice. Thus the laboratory had 
therefore developed a replication-deficient human adenovirus type 5 expressing shRNA 
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NPPRV1 (rAd_NPPRV1shRNA) against the nucleoprotein of PPRV and tested it in vitro 
(personal communication), showing it was capable of reducing PPRV induced cytopathic 
effects (CPE) as well as PPRV titers (Fig.15).   
 
Table 1: Inhibition of PPRV N gene expression and PPRV titers by three effective siRNAs 
  
siRNA 
name 
siRNA Sequence Position Fold Inhibition of 
PPRV Titer 
% Inhibition of 
NPPRV expression 
NPPRV1 Sense 5′-GGAUCAACUGGUUUGAGAAtt-3′  480-498 10,000 90+- 2 
NPPRV6 Sense 5′- GGCGGUUCAUGGUAUCUCUtt-3′        741-759 100 >80 
NPPRV7 sense 5′-GCAUUAGGCCUUCACGAGUtt-3′ 899-917 100 >80 
 
 
 
 
(a) 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
Figure 15: (a) Inhibition of cytopathic effects (CPE) in Vero cells, and (b) PPRV progeny by 
rAd_NPPRVshRNA, at various time intervals after challenge with PPRV MOI 0.1. 
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AIMS AND OBJECTIVES 
The aim of this project was the effective delivery of siRNA or shRNA in vivo against peste 
des petits ruminants virus. For the purpose, firstly the viral and chemical vectors were tested 
in the course of study to find efficient delivery vectors in vitro. The in vivo experiments were 
initially conducted on goats under L3 bio-security conditions. However, due to ethical, 
economical, and bio-security issues, a mouse model based upon bioluminescent imagery is 
developed for in vivo testing of various siRNA/shRNA delivery vectors.  
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PART. 1: 
 
In vivo delivery of siRNA/shRNA against PPRV infection by adenoviral and 
cationic liposome vectors 
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1.1 Introduction 
RNAi based antivirals can be administered in vivo either in the form of chemically 
synthesized siRNA molecules which are delivered by chemical vectors or these can be 
delivered in the form of shRNA through viral vectors (for further information, see Review of 
the Literature chapter). At the start of this work, siRNAs capable of effective inhibition of 
PPRV replication in vitro were available. Since commercial chemical vectors prove too 
expensive when used for in vivo delivery of large quantities of siRNAs in animals of large 
size like goats, here a cationic lipid based formulation was developed for delivery of siRNAs. 
In this study, this cationic lipid as well as a recombinant adenovirus expressing the shRNA 
NPPRV1 (rAd_NPPRV1shRNA) were tested about their capacity to deliver the siRNA/shRNA 
NPPRV1 and inhibit PPRV replication in goats.  
 
 
1.2 Material and Methods 
 
1.2.1 Cell culture 
Vero cells (European Collection of Cell Culture, France 84113001) were maintained in 
Eagle’s Minimum Essential Medium (EMEM) supplemented with 10% (vol/vol) heat-
inactivated foetal bovine serum (FBS), 2 mM L-glutamine at 37°C with 5% CO2 in a 
humidified incubator. Vero cells were used for the production and titration of PPRV and 
transfection experiments. The 293A cells (Invitrogen) were propagated in Dulbecco’s 
modified Eagle’s medium supplemented with 10% (vol/vol) FBS at 37°C with 5% CO2. 
 
1.2.2 Production of PPRV 
The vaccine strain of PPRV (Nigeria 75/1) [351] and a virulent strain of PPRV Côte d’Ivoire 
89 (CI 89) were propagated by infecting Vero cells, cultured in 75 cm2 cell culture flasks with 
EMEM having 5% FBS at multiplicity of infection (MOI) of 0.1 CCID50/ml. When viral 
cytopathic effect (CPE) was almost complete (~80%), the cells were freeze-thawed 3 times 
and aliquots were stored at -80°C. Viral titration was performed in 96 well cell culture plates, 
in which 100 µl of 10 fold serial dilutions of PPRV in EMEM were added to 100 µl of Vero 
cell suspension (20,000 cells). For each viral dilution, 10 wells were used. The viral titers 
were calculated by end point titration method of Reed and Muench [352] and expressed as 
cell culture infectious cytopathic doses for 50% of the tests (CCID50 /ml). 
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1.2.3 Preparation of liposomes for in vitro validation of siRNA delivery 
A liposome formulation (M2b) based up on a 1/1/0.5 (m/m) combination of cationic lipid 1,2-
dioleoyl-3-trimethylammonium-propane-chloride salt (DOTAP), the neutral lipid 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and an anionic lipid cardiolipin was 
developed and tested in vitro for delivery of siRNA NPPRV1. DOTAP, DOPE, and 
cardiolipin were each dissolved in ethanol (90%) to have a concentration of 25µg/µl. Then, 
20µl each of DOTAP and DOPE were mixed in ratio of 1/1 (m/m). Solution was 
homogenized by vortexing for 10 seconds and incubated at room temperature for 15 minutes. 
The tube containing the lipid mixtures was vacuum centrifuged overnight at room temperature 
to obtain a dry lipid film. Then, 10 µl of cardiolipin was added to the tube with lipid film and 
vortexed until film was completely dissolved. Next, 190 µl of sterile water (filtered by 0.2 
μm) was rapidly added with pipette, in a single step, under hood and vortexed immediately 
for 10 seconds. The solution was incubated overnight at 4oC before using the liposomes for 
making complexes.  
 
1.2.3.1 Transfection in vitro of siRNA with cationic liposomes and challenge with 
PPRV 
Vero cells of 48 hours of growth were trypsinized and 105 cells were cultured in 24 well cell 
culture plates using EMEM supplemented with 10% (vol/vol) FBS, 2 mM L-glutamine at 
37°C with 5% CO2 in a humidified incubator. At the time of transfections, cell layers were 
more than 80% confluent. Before use, liposome solution (6.25 mg/ml) was homogenized by 
light vortexing and placed at room temperature for 15 minutes. Next, it was used either 
undiluted for high siRNA/lipid mass ratios (1/90, 1/70, and 1/56) or diluted 1/9 in NaCl (150 
mM, pH 5.2) for lower siRNA/lipid ratios (1/12.4, 1/10, and 1/6.2) to have a concentration of 
0.694 mg/ml.  
The synthetic siRNAs, NPPRV1 which targets N gene of PPRV and the irrelevant siRNA 
NRPV1 [3] targeting N gene of rinderpest virus, were used for transfection. For complex 
formation, 0.41 µg of each siRNA was diluted to a final volume of 45 µl/well in RNAse free 
water. The liposomes were diluted variably (according to variable mass ratios to be used 
against siRNA) in NaCl solution to a final volume of 45 µl/well and mixed. For lipoplex 
formation, the siRNA solution was rapidly injected upon liposome solution in one step, 
pipetted three times, and lightly vortexed. The complexes were allowed to form at room 
temperature for 30 minutes. Finally, 90 µl of complexes were added to each well of 24 well 
cell culture plates, already having 210 µl of EMEM, resulting in a final siRNA concentration 
of 100 nM. After five hours of incubation at 37°C and 5% CO2, the complexes were removed 
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and fresh EMEM supplemented with 5% FBS and glutamine was added to each well. 
Lipofectamine™ 2000 (Invitrogen) was used as control liposome, according to the supplier's 
protocol.  
 
Twenty four hours post-transfection, the cells were infected with the PPRV vaccine strain 
Nigeria 75/1 using a MOI of 0.1 CCID50 per cell. For that, cell culture medium was removed 
and viral inocula were added in EMEM without serum in a final volume of 200 µl in a 24 well 
cell culture plates. After one hour of incubation at 37°C with 5 % CO2, EMEM with 5% FBS 
was added to have a final volume of 1 ml per well and plates were again incubated. The 
positive controls for transfection consisted of the Vero cells transfected with the irrelevant 
siRNA NRPV1 and infected with the same MOI of PPRV. Moreover, the cells serving as 
negative controls were similarly transfected but not infected with PPRV. Efficacy of siRNA 
was assessed on the inhibition of N protein and CPE produced by PPRV compared to the 
positive control. Efficacy of M2b liposomes was compared to Lipofectamine™ 2000. 
 
1.2.3.2 Measurement of PPRV N protein expression and cytopathic effects (CPE) 
of PPRV in siRNA transfected cells 
The relative expression of PPRV N protein was used as a measure of the N gene knock-down 
by siRNA NPPRV1 transfected with different liposome formulations. The expression of the N 
protein was quantified by immunofluorescence staining and reading by flow cytometry 96 
hours post-infection, as described by Servan de Almeida et al. [353]. To measure the 
inhibition of CPE, cell layer was checked by microscopy 96 hours after PPRV challenge. 
Scores ranging from 0% to 100% were attributed depending on the severity of CPE (Fig. 16).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Percentage scale of CPE produced by PPRV on Vero cells. 
0 % 25 %  50% 
75 100 %
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1.2.4 Construction of recombinant adenovirus rAd_NPPRV1shRNA  
Recombinant adenovirus expressing shRNA NPPRV1 (rAd_NPPRV1shRNA) available at the 
beginning of this work, was constructed using the commercial kit BLOCK-iTTM Adenoviral 
RNAi Expression System according to the supplier instructions (Invitrogen). Briefly, the 
double-stranded oligo encoding the shRNA NPPRV1 was cloned into the pENTRTM/U6 
plasmid (Invitrogen) encompassing the human U6 promoter, and a polymerase III terminator. 
Recombination was performed using pENTR/U6/ NPPRV1shRNA clone and pAD/ BLOCK-
iTTM –DEST vector to generate an adenovirus expression clone. The expression clone was 
transfected into 293A cells to produce the rAd_NPPRV1shRNA stock (Fig. 17). 
 
 
 
Figure 17: Schematic representation of (a) siRNA NPPRV1 sequence (b) shRNA sequence,         
(c) plasmid shuttle vector, and (d) expression plasmids for rAd_NPPRV1shRNA.  
 
 
 
 
Pol III terminatorshRNA NPPRV1u6 Promoter
Sense: 5'-GGAUCAACUGGUUUGAGAAtt-3'; Antisense: 3'-ttCCUAGUUGACCAAACUCUU-5' 
Antisense Sequence Loop SequenceSense SequenceLinker 
Top Strand    
5'-CACCGGATCAACTGGTTTGAGAACGAATTCTCAAACCAGTTGATCC-3' 
Bottom Strand  
5'-AAAAGGATCAACTGGTTTGAGAATTCGTTCTCAAACCAGTTGATCC-3' 
b. shRNA Sequence 
a. siRNA  sequence  
NPPRV1
c. Plasmid Shuttle Vector 
    pENTRshRNA_NPPRV1 
d. Expression construct 
for rAd NPPRV1shRNA
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1.2.5 In vivo delivery of siRNA/shRNA by “M2b” liposome and rAd_NPPRV1shRNA 
vectors 
 
1.2.5.1 Preparation of liposomes and lipoplexes for in vivo application 
DOTAP, cardiolipin sodium salt from bovine heart, and DOPE were purchased from Avanti 
Polar Lipids, Inc. Endotoxin free water was used for siRNA dilution as well liposome 
preparation. An inherent problem occurred in scaling-up experiments from cell cultures to 
large animals like goats is the sense that larger volumes as well as concentrated reagents had 
to be used to achieve rational injectable doses. A siRNA/lipid ratio of 1/6.2 was intended to 
be used for experiment in vivo but due to problem of precipitation at this ratio, a ratio of 
1/2.08 was retained.   
 
For this preparation, 20 ml of ethanol (90%) were added to 500 mg of cardiolipin lipid and 
vortexed for one minute. 1 mg of each DOPE and DOTAP powders were diluted in 
cardiolipin solution resulting in a final lipid concentration of 125 mg/ml. The mixture was 
then heated in a water bath at 50°C for 1h. Eighty milliliters of water pre-warmed to 50°C was 
rapidly injected onto 20 ml of dissolved lipids to have a liposome solution in a final lipid 
concentration of 25 mg/ml. To prepare working solution of the liposomes, original liposome 
solution (DOTAP+DOPE+cardiolipin 25 mg/ml) was diluted three times in NaCl (0.9%, pH 
5.2) to have a final lipid concentration of ~8.33 mg/ml. The solution was vortexed for mixing. 
The 50 mg lyophilized siRNA NPPRV1 was diluted in endotoxin free water to a final 
concentration of 2 mg/ml and solution was well mixed.  
 
For lipoplex preparation, liposomes were first extruded three times with a discontinuous 
extruder (Lipofast-extruder, Avanti Polar Lipids, Inc.) through 100 nm filter. The lipoplexes 
were prepared using siRNA/lipid mass ratio 1/2.08 (12mg of siRNA for 25 mg of lipids). The 
complexes were allowed to form at room temperature for 30 minutes. Finally, Dulbecco’s 
Minimum Essential Medium (DMEM) was added to complete 30 ml, which was the volume 
injected intravenously to the goats. 
  
1.2.5.2 Experimental design 
For the in vivo experiment, thirty goats were confined in the Experimental Infectiology 
Platform (PFIE) of INRA (Nouzilly, France). The animals were pre-treated with 
rAd_SCRshRNA, rAd_NPPRV1shRNA  or lipoposomes M2b complexed with siRNA NPPRV1 
and subsequentlychallenged with the virulent strain of PPRV - Côte d’Ivoire-89 (CI 89). The 
 81  
animals were divided in 3 groups of 10 animals each. Group-1 and Group-2 were injected 
intravenously with 0.5x1010 CCID50/ml of an irrelevant adenovirus rAd_SCRshRNA (Vector 
Biolabs) and rAd_NPPRV1shRNA, respectively (Fig. 18). Forty-eight hours later, the animals 
were challenged with 0.5x105 CCID50/goat of the virulent strain of PPRV - Côte d’Ivoire-89 
(CI 89). Group-3 was injected with 3 doses of M2b liposome+siRNA NPPRV (12 mg 
siRNA/dose/day) and similarly challenged 48 hours after first dose administration. Animals 
were examined daily by a veterinarian for clinical signs and a score according to the severity 
of signs was accorded. Blood samples for virus detectionwere collected on day 1 to day 14 
and the day 20 post-challenge. At the end of experiment, animals were euthanized by 
injection of barbiturates. 
 
 
 
 
Figure 18: Experimental design for in vivo delivery of shRNA/siRNA.  
 
 
 
 
 
 
0.5 x 1010 particles 0.5 x 1010 particles siRNA 12 mg D0 
D1 siRNA 12 mg + PPRV (IC-89) 0.5 x 105 TCID50
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1.2.5.2.1. Assignment of clinical scores  
Different clinical scores were assigned according to severity of clinical signs/lesions 
• Hyperthermia (equal or greater than 39°C) = 1 point (pt) 
• Respiratory difficulties : 
o nasal discharge and lacrimation (mild) =  1 pt 
o nasal discharge and lacrimation (severe) =  2 pts 
o cough= 1 pt 
• Disorder of digestive system : 
o mild stomatitis (oral lesions) = 1 pts 
o necrotic stomatitis (oral lesions) = 3 pts  
o diarrhea  = 3 pts 
• General behavior  : 
o good = 0 pt 
o apathy = 1 pt 
o prostration = 2 pts 
o decubitus = 3 pts 
• Mortality = 20 pts  
 
 
1.2.5.2.1.1 Association of scores for ocular and nasal discharges:  
Since the mild nasal discharge can be confusing for scoring, more weight was given to scores 
for ocular discharge than for nasal discharge and similarly if the two signs coexist.  
 
Ocular discharge Nasal discharge Combined score 
0 0 0 
0 1 0 
1 0 1 
1 1 1 
0 2 1 
2 0 2 
2 1 2 
1 2 2 
2 2 3 
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1.3 Results 
 
1.3.1 In vitro inhibition of PPRV N protein expression by siRNA NPPRV1 transfected 
with liposome formulation using various siRNA/lipid mass ratios  
Efficacy of siRNA NPPRV1 transfection was measured as % inhibition of nucleoprotein 
expression and reduction of CPE by PPRV as compared to a positive control which was cell 
transfected by an irrelevant siRNA and PPRV-infected. Initially, high siRNA/lipid mass ratios 
(1/90, 1/70, and 1/56) were tested for transfection efficiency in the absence of serum. The 
transfection time was three hours. The M2b formulation at siRNA/lipid ratio of 1/56 could 
efficiently transfect siRNA NPPRV1 resulting in an inhibition of PPRV N protein expression 
up to 64.5% as measured by flow cytometry (Fig. 19). M2b formulation at high siRNA/lipid 
ratio of 1/56 showed visible toxic effects upon Vero cells. As ultimate objective was to use 
liposome formulation for siRNA delivery in vivo, low toxicity was considered. 
 
 
 
Figure 19: Inhibition of PPRV N protein expression by siRNA NPPRV1 after transfection 
with liposome formulation M2b.  
 
 
 
Therefore, lower siRNA/lipid ratios (1/12.4, 1/10, and 1/6.2) were tested for transfection 
efficiency of siRNA NPPRV1, both in the absence and in the presence of various 
concentrations of goat serum. The siRNA/lipid ratio of 1/6.2 was the lowest which could 
inhibit CPE produced by PPRV to about 80% when transfection was performed in absence of 
goat serum, while CPE inhibition was about 45% upon transfection in presence of 60% goat 
serum (Tab. 2 and Fig. 20). Therefore, the liposome formulation M2b with siRNA/lipid ratio 
of 1/6.2 was selected for in vivo delivery of siRNA NPPRV1. 
1.6
80.9
31.0 32.6 29.8
0
10
20
30
40
50
60
70
80
90
100
N 
vi
ra
l p
ro
te
in
 e
xp
re
ss
io
n 
(%
)
Vero PPRV M2b 1/90 M2b 1/70 M2b 1/56
 84  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Effect of M2b liposome mediated transfection of siRNA NPPRV1, using 
siRNA/lipid ratio of 1/6.2 (m/m), upon CPE production by PPRV 96 hours after challenge 
with MOI 0.1. (a) non-infected Vero cells (b) PPRV infected Vero cells (c) transfection in 
medium without FBS (d) transfection in presence of 30 goat serum  
 
 
 
 
Table 2: Inhibition of CPE produced by PPRV in Vero cells transfected with siRNA 
NPPRV1 transfected by M2b liposome formulation using various siRNA/lipid (m/m) ratios. 
 
M2b (DOPE+DOTAP+Cardiolipin) 1/1/0.5   % Goat serum % Inhibition of CPE 
 
siRNA/M2b 1/12.4 
10 75 
30 50 
60 40 
 
siRNA/M2b 1/10 
10 80 
30 50 
60 45 
 
siRNA/M2b 1/6.2 
 
10 80 
30 50 
60 45 
Lipofectamine™ 2000 0% 85 
 
(b)(a)  
(d) (c) 
Cells transfected with 
irrelevant siRNA 
Cells transfected with 
siRNA NPPRV1 
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1.3.2 In vivo delivery of siRNA by M2b liposome formulation and recombinant 
adenoviruses  
 
1.3.2.1 Clinical scores of animals treated with siRNA+M2b, rAd_NPPRV1shRNA 
and rAd_SCRshRNA. 
The group of animals receiving siRNA in the form of lipoplexes (Group-3), had lower scores 
for occulo-nasal discharges and stomatitis at day 14 to day 20 post-siRNA/shRNA 
administration as compared to the positive control group (Group-1) and to the group receiving 
rAd_NPPRV1shRNA (Fig. 21), but the difference was not statistically significant (Mann–
Whitney U test, p<0.01). While for diarrhea and body temperatures, scores were in fact higher 
for both treatment groups (Group-2 and Group-3) as compared to the positive control group 
(Group-1) (Fig. 21).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Clinical scores for occulo-nasal discharges, stomatitis, temperature and diarrhea 
for the group of animals treated with M2b liposome+siRNA NPPRV, rAd_NPPRV1shRNA and 
rAd_SCRshRNA. 
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1.4 Discussion 
There could be numerous possible reasons for absence of significant therapeutic effect of 
liposome mediated siRNA delivery and shRNA delivery by the recombinant adenovirus. 
Firstly, due to problem of precipitation, it was not possible to form lipoplexes using an 
optimal siRNA/lipid ratio of 1/6.2 and therefore a ratio of 1/2.08 had to be used which is three 
times lower than expected. This ratio was later tested in vitro and it was actually less active 
and could merely inhibit siRNA mediated inhibition of CPE to about 20 %.  
 
Secondly, the fact that morbilliviruses are primarily lymphotropic and secondarily 
epitheliotropic [61, 124, 132], highlights the importance to deliver siRNA/shRNA into the 
lymphatic tissues in vivo. The wild-type morbilliviruses use the SLAM or CD150 as a 
primary receptor [8, 9], which is found on activated T cells, B cells, thymocytes, macrophages 
and dendritic cells (DCs) [121, 122]. It is reported that measles virus selectively unabled to 
recognize human SLAM (SLAM-blind) receptors, induced neither clinical signs nor 
significant viremia, proving that efficient SLAM recognition (on lymphatic tissues) is 
necessary for viral virulence and pathogenesis [131]. Thus the infection of lymphatic tissues 
plays a major role in measles virus pathogenesis. However, the lymphatic tissues are not only 
hard to transfect with liposomes [13] but are also difficult to transduce with adenovirus 
vectors [354]. Liu et al., tested four different liposome based transfectants, including 
Lipofectamine™ 2000, for siRNA delivery into human T lymphocytes but found no silencing 
effect [13]. Similarly, in our attempt at transfecting siRNA NPPRV1 with Lipofectamine™ 
2000 and subsequent infection of peripheral blood mononuclear cells (PBMCs) of goats with 
vaccine strain of PPRV, we did not find any inhibitory effect upon NPPRV expression (data 
not shown). Moreover, it is reported that human adenovirus type 5 could transduce only 4% 
of human T cells [354]. Similarly we tested transduction of goat PBMCs with human 
adenovirus type 5 expressing green fluorescent protein (GFP) and found that only 3% of 
PBMCs could be transduced (data not shown).  
 
There are studies that report successful therapeutic effect of adenoviruses expressing shRNA 
in vivo against foot and mouth disease virus (FMDV) [15, 16].  Chen et al., could protect 
swine from a major clinical disease through adenoviral vectors targeting FMDV, however 
they could only achieve a limited inhibition of FMDV infection, and they sited the different 
tissue distribution of rAd5 and FMDV as the reason [23]. The better efficiency of adenoviral 
vectors against FMDV infection in vivo may be due to relative similarity of tropism of the two 
viruses. Both the adenovirus type 5 and field isolates of FMDV use arginine-glycine-aspartate 
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(RGD) motifs on their capsids to interact with the αvβ subclass of integrins for internalization 
into host cells, although FMDV uses αvβ6 as its primary receptor and it can use αvβ3 [355, 
356], while adenovirus type 5 uses αvβ3 and αvβ5 [312]. Finally, the fact that lymphatic tissues 
are primary sites of replication for morbilliviruses and are very difficult to transduce or 
transfect transiently as compared to epithelial tissues, can preclude therapeutic implications. 
Thus from therapeutic point of view, in vivo delivery of siRNAs/shRNAs lymphatic tissues, 
in addition to epithelial tissues, may also be  indispensable to control morbillivirus infections.  
 
This experiment in vivo showed that better viral and chemical vectors are needed for future in 
vivo delivery and experiments on animals of large size like goats under L3 bio-security, are 
not only cumbersome, but are also prohibitively expensive. Therefore, a more economical and 
practical small animal model is needed for initial screening of vectors before their ultimate 
test in small ruminants. 
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PART 2: 
 
Potential of adenovirus and baculovirus vectors and cell penetrating 
peptides (CPPs) for the delivery of shRNA/siRNA against peste des petits 
ruminants virus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1 Introduction 
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Therapeutic application of siRNAs requires correct delivery of the molecules into the cell 
cytoplasm which poses significant problems in vivo. Successful delivery of siRNAs/shRNAs 
by chemical and viral vectors in vitro is not always reflected in the form of effective in vivo 
results. Our preliminary attempt at in vivo delivery of siRNA/shRNA through liposome and 
adenovirus vectors did not give promising results (for further information, see Chapter 1 of 
this document). This entailed us to search for more efficient viral or non-viral vectors which 
could be possibly used for future siRNA/shRNA delivery in vivo.  
 
The adenoviruses were one of the first viral vectors to be used for gene therapy in vitro [305] 
and are the most commonly utilized viral vectors [306]. Replication deficient adenoviruses 
have been successfully used in vitro and also in vivo as shRNA delivery vectors against 
numerous viruses including measles virus [221, 319, 320] . Adenoviruses have advantages 
over other viral vectors as they can be produced in high titers and can transduce a broad range 
of cell types [357]. Whereas use of baculoviruses like Autographa californica multiple 
nucleopolyhedrovirus (AcMNPV), as shRNA delivery agents have shown promising results 
in vitro against viral infections [332, 333] [334, 335]. Moreover, these recombinant 
Baculovirus gene transfer into Mammalian cells, known as BacMam baculoviruses, having 
mammalian cell-active expression cassettes, are capable of transducing a wide variety of cells 
including non-dividing cells [330] and primary cells [331].  
 
Among the various chemical vectors used for siRNA delivery, cell penetrating peptides 
(CPPs) are unique since they produce very low or undetectable cytotoxicity [264]. PepFect6 
(PF6) and PepFect14 (PF14) are new chemically modified CPPs, developed by team of Ülo 
Langel (Department of Neurochemistry, Stockholm University, Sweden), which form stable 
non-covalent complexes with siRNA and are capable of efficient transfection of siRNAs 
[358] (Fig. 22). Most of siRNA molecules transfected by chemicals, remain trapped in 
endosomes and are ultimately destroyed, therefore the trafficking of siRNAs from endosomes 
into the cytoplasm represents a major rate-limiting step for many delivery approaches [359]. 
The presence of a modified stearyl moiety on both PF6 and PF14 help these peptides to have 
better interaction with plasma membrane whereas a chloroquine analogue coupled to 
PepFect6 results in an efficient endosomal escape [358]. Among the two peptides, the PF14 is 
more serum resistant [33], whereas PF6 can deliver the siRNAs more efficiently into various 
cell types including lymphocyte suspension cells and primary embryonic stem cells [360]. 
The PF6 mediated delivery of siRNAs is independent of cell confluence and does not induce 
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transcriptomic or proteomic changes [360]. Moreover, it is capable of efficient delivery of 
siRNA in vivo in mouse models as well [360].  
 
               Peptide Sequence 
PepFect 6 Stearyl-AGYLLGK[KK2sa4qn4]INLKALAALAKKIL-NH2 
PepFect 14 Stearyl-LLOOLAAAALOOLL -NH2 
 
Figure 22: Sequences of Pepfect6 and PepFect14 peptides [358]  
 
In this study, a recombinant replication deficient human adenovirus type 5 and a recombinant 
baculovirus expressing shRNA (NPPRV1) were compared for their inhibition activity against 
PPRV replication in vitro, referring to the inhibition previously achieved with siRNA 
delivered by transfecting reagents. Additionally, two novel chemically modified CPPs, the 
PF6 and PF14 [358], have also been tested for delivery of siRNA NPPRV1 and inhibition of 
N gene expression by PPRV in vitro. These three delivery systems are potential candidates for 
in vivo studies after validation in vitro. 
 
2.2 Material and Methods 
 
2.2.1 Cell culture 
Vero cells were maintained in Eagle’s Minimum Essential Medium (EMEM) supplemented 
with 10% (vol/vol) heat-inactivated bovine calf serum (FBS), 2 mM L-glutamine at 37°C and 
5% CO2 in a humidified incubator. Vero cells were used for the production and titration of 
PPRV and for transduction with the recombinant baculovirus (rBac_NPPRV1shRNA) and the 
recombinant adenovirus (rAd_ NPPRV1shRNA) vectors. The 293A cells (Invitrogen) were used 
for the amplification and titration of rAd_NPPRV1shRNA. These cells were propagated in 
Dulbecco’s modified Eagle’s medium supplemented with 10% (vol/vol) FBS at 37°C with 5% 
CO2. For production and titration of rBac_NPPRV1shRNA and rBac_eGFPshRNA, SF-21 cells 
were cultured in Grace's insect cell culture medium supplemented with 10% (vol/vol) FBS at 
27°C. 
 
2.2.2 Preparation of recombinant viruses 
2.2.2.1 Construction of adenovirus rAd_NPPRV1shRNA 
The construction of the replication deficient adenovirus vector expressing shRNA NPPRV1 
(rAd_ NPPRV1shRNA) is already described in Chapter 1.  
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2.2.2.2 Construction of the baculovirus rBac_NPPRV1shRNA 
Baculovirus vectors expressing shRNA NPPRV1 (rBac_NPPRV1shRNA) and a shRNA against 
GFP gene (rBac_EGFPshRNA) were constructed and provided to us by Dr. Günther M. Keil 
(Friedrich-Loeffler-Institut, Germany). Briefly, an insect cell-active GFP-expression cassette 
was integrated into the commercially available pFastBac Dual to yield plasmid 
pBacPH_GFPpolyA [361]. This plasmid was used to integrate a blunt ended BsrG1 fragment 
(400 bp) from pENTR/U6/ NPPRV1shRNA (Fig. 23). The resulting plasmid 
pBacPH_GFP_NPPRV-1shRNA was used to generate the recombinant baculovirus 
(rBac_NPPRV1shRNA), as recommended in the Bac-to-Bac® Baculovirus Expression Systems 
kit (Invitrogen). rBac_NPPRV1shRNA was amplified on SF21 cells. The budded baculovirus 
from insect cell culture medium was concentrated by ultracentrifugation on sucrose gradient 
and the viral titers were determined by end-point titration method of Reed and Muench (1938) 
and expressed as CCID50 /ml. 
 
 
Figure 23: Schematic representation of (a) siRNA NPPRV1 sequence (b) shRNA sequence,         
(c) plasmid shuttle vector, and (d) expression plasmid for rBac_shRNA_NPPRV1. 
 
Pol III terminatorshRNA NPPRV1u6 Promoter
Sense: 5'-GGAUCAACUGGUUUGAGAAtt-3'; Antisense: 3'-ttCCUAGUUGACCAAACUCUU-5' 
AntisenseLoop SequenceSense SequenceLinke
Top Strand    
5'-CACCGGATCAACTGGTTTGAGAACGAATTCTCAAACCAGTTGATCC-3' 
Bottom Strand  
5'-AAAAGGATCAACTGGTTTGAGAATTCGTTCTCAAACCAGTTGATCC-3' 
b. shRNA Sequence 
a. siRNA  sequence  
NPPRV1
c. Plasmid Shuttle Vector 
    pENTRshRNA_NPPRV1 
d. Expression construct 
for rBac_NPPRV1 
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2.2.3 Adenoviral and baculoviral transductions and PPRV challenge: 
To investigate the interfering activity of shRNA expressed by rBac_NPPRV1shRNA and    
rAd_NPPRV1shRNA, the Vero cells were first transduced with various transduction doses 
(MOIs of 25, 50, 100, and 200) and challenged with a low dose of PPRV (MOI of 0.01). 
Later, the effect of transduction with higher MOIs of the two recombinant viruses (MOIs of 
100, 200, 300, and 400) and a challenge with both a low (MOI 0.01) as well as a high (MOI 
of 0.1) dose of PPRV were assessed.  
 
For transductions with the recombinant adenoviruses and baculoviruses, Vero cells of 48 
hours were trypsinized and 105 cells were plated in 24 well cell culture plates. Twenty four 
hours after plating, culture medium was removed. Then, various MOIs of rAd_NPPRV1shRNA 
and an adenovirus expressing scrambled shRNA, rAd_ SCRshRNA (Vector Biolabs), were 
added in a final volume of 400 µl per well and the plates were incubated overnight at 37°C, 
5% CO2. Next, the inocula were removed and 1 ml of EMEM with 5% of FBS was added to 
each well. For baculovirus transduction, the culture medium was removed and the cells were 
washed twice with Dulbecco’s phosphate-buffered saline containing calcium and magnesium 
(Sigma Aldrich). Then, rBac_NPPRV1shRNA and rBac_eGFPshRNA expressing an irrelevant 
shRNA were added to the wells using various MOIs in a final volume of 300 µl per well. The 
plates were incubated for 30 min at 27°C under agitation (100 rpm) and then centrifuged at 
27°C for 1 hour at 600 g. Inocula were discarded and 1 ml EMEM was added to each well.  
 
Cells were finally challenged with PPRV (MOIs 0.01 or 0.1), 24 and 72 hours post-
transduction with the recombinant baculovirus and adenovirus, respectively. To assess the 
antiviral effect, PPRV cytopathic effects (CPE) were scored from 0 to 100%, at 72 and 96 
hours post-infection with PPRV MOI 0.1. In addition, cell supernatants were collected 48, 72 
and 96 hours post-infection and titrated using 10 fold serial dilutions according to Reed & 
Muench [352]. Viral titers were expressed in CCID50/ml. The relative expression of PPRV 
nucleoprotein was also measured 96 hours post-infection by flow cytometry as described by 
Servan de Almeida et al. [353]. Moreover, to confirm that the inhibitory effect upon PPRV 
replication was due to specific silencing by the two recombinant viruses, Vero cells were 
transduced and challenged with rinderpest virus (RPV). The two recombinant viruses never 
showed any inhibitory effect upon CPE produced by RPV (data not shown). 
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2.2.4 Transfection of siRNA NPPRV1 with PF6 and PF14 
The transfection efficacy of PF6 and PF14 was tested on 6 x 104 Vero cells grown in 24 well 
cell culture plates. After 24 hours of growth, medium was removed, cell layer was washed 
twice with PBS, and 450 µl of DMEM (either without or with variable FBS concentrations) 
was added to each well. The siRNAs and PepFects were dissolved in RNAse free water. The 
siRNAs were complexed with PF6 using a molar ratio of 1/10. While for PF14, siRNA/PF14 
molar ratio of 1/10 was initially tested and found less efficient upon NPPRV protein 
expression. Therefore, siRNA/PF14 ratios of 1/5, 1/10, and 1/15 were tested. The complexes 
were incubated at room temperature for one hour. Next, 50 µl of complexes were added to the 
duplicate wells. Firstly, final siRNA concentrations of 12.5, 25, 50, and 100 nM /well were 
transfected with PF6 in the absence of FBS. Later, the siRNA concentration of 100 nM (the 
most effective concentration) was transfected with PF6 in the presence of various FBS 
percentages. For transfection with PF14, a final siRNA concentration of 100 nM was used and 
transfections were performed in the medium with no or variable FBS percentages. Higher 
siRNA/PF14 ratios and FBS percentages could not be tested owing to limited availability of 
PF14. Plates were incubated for 4 hours at 37°C with 5% CO2. Next, one ml of EMEM with 
5% FBS was added to the wells and plates were further incubated for 20 hours at 37°C with 
5% CO2. Finally, the cells were challenged with PPRV at MOI of 0.1 and relative expression 
of PPRV nucleoprotein was measured by flow cytometry, 96 hours post-challenge. The 
efficacy of siRNA transfection was measured as % inhibition of nucleoprotein expression by 
PPRV as compared to an irrelevant siRNA (targeting nucleoprotein gene of RPV).  
Lipofectamine™ 2000 (Invitrogen) was used as a control of siRNA transfection, according to 
the supplier's protocol. 
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2.3 Results 
 
2.3.1 rBac_NPPRV1shRNA and rAd_NPPRV1shRNA challenged with PPRV MOI of 0.01 
inhibit PPRV progeny production 96 h post challenge 
Both recombinant viruses could inhibit PPRV progeny in vitro when transduced cells were 
challenged with PPRV at MOI of 0.01. However, the rAd_NPPRV1shRNA at MOI of 200 could 
only reduce PPRV titers to 0.79 log10 with (Fig. 24). In contrast, the rBac_NPPRV1shRNA in 
the same MOI could inhibit PPRV titers by more than 2 log10 (Fig. 24).   
 
 
 
Figure 24: Inhibition of PPRV progeny production by rAd_NPPRV1shRNA and 
rBac_NPPRV1shRNA 96h post-challenge with PPRV MOI of 0.01.  
 
 
2.3.2 Effect of higher transduction doses of rBac_NPPRV1shRNA and     
rAd_NPPRV1shRNA and challenge doses of PPRV, upon inhibition of PPRV 
progeny production after over time 
The effects of transduction with higher MOIs of the two recombinants on a higher challenge 
dose of PPRV and the time/effect relationship upon PPRV progeny production were assessed. 
Vero cells were transduced with the two recombinant viruses using MOIs of 100, 200, 300, 
and 400 and challenged with a low (MOI of 0.01) and high (MOI of 0.1) doses of PPRV.  
 
The rAd_NPPRV1shRNA transduction at MOI of 200, after challenge with PPRV MOI of 0.01 
and 0.1, inhibited PPRV progeny titers to 0.5 and 0.7 log10, respectively (Fig. 25). The CPE 
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reduction rarely exceeded 50% (Tab. 3). Transduction with higher MOIs of 
rAd_NPPRV1shRNA did not improve the performances of the adenovirus but, in contrast, had a 
toxic effect on the cell culture. 
 
 
 
Figure 25: Inhibition of PPRV progeny by rAd_NPPRV1shRNA 48h, 72h and 96h post-
infection with PPRV MOIs of 0.1. rAd_NPPRV1shRNA expressed shRNA against NPPRV 
gene while the rAd_ SCRshRNA expressed a scrambled shRNA and was used as a control. 
 
 
In contrast, the rBac_NPPRV1shRNA, at MOI of 400, could induce a maximum inhibition of 
PPRV titers by about 2.1 log10, 96 hours post-challenge with PPRV MOI of 0.01 (Fig. 26a). 
While upon challenge with PPRV MOI of 0.1, rBac_NPPRV1shRNA transduction at MOI of 
400 inhibited the PPRV CPE up to 87.5% and reduced PPRV progeny virus titers by 2.19 
log10 at 72 and 96 hours post-infection, respectively (Tab. 3 and Fig. 26b). This inhibitory 
effect on PPRV replication was reflected by an up to 73% reduction of PPRV nucleoprotein 
expression by rBac_NPPRV1shRNA measured by flow cytometry, 96 hours post-challenge 
(Fig. 27). No difference in CPE expression by PPRV was found between un-transduced and 
PPRV infected cells and cells transduced with the two recombinant viruses expressing 
irrelevant or scrambled shRNA and infected by PPRV. 
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Figure 26: Inhibition of PPRV progeny virus production by rBac_NPPRV1shRNA 48h, 72h 
and 96h post-infection with PPRV MOIs of (a) 0.01 (b) 0.1. rBac_ eGFPshRNA expressing an 
irrelevant shRNA was used as control. 
 
 
1.0E+02
1.0E+03
1.0E+04
1.0E+05
1.0E+06
1.0E+07
C
C
ID
50
/m
l
Virus
control
NPPRV1
100
eGFP  
100
NPPRV1
200
eGFP  
200
NPPRV1
300
eGFP   
300
NPPRV1
400
eGFP  
400
MOIs of rBac shRNA 48H 72H 96H
 97  
0.4
88.3
52.5
85.0
37.4
84.0
29.0
86.4
23.4
86.3
0
10
20
30
40
50
60
70
80
90
100
N
 v
ira
l p
ro
te
in
 e
xp
re
ss
io
n 
(%
)
Vero PPRV NPPRV1
100
eGFP
100
NPPRV1
200
eGFP
200
NPPRV1
300
eGFP
300
NPPRV1
400
eGFP
400
MOIs of rBac_shRNA
Table 3: Effect of rBac_NPPRV1shRNA and rAd_NPPRV1shRNA upon percentage of CPE 
induced by PPRV at 72h and 96h post infection. 
 
 72h 96h 
Virus control 75 100 
rBac_NPPRV1shRNA MOI 100 25 50 
rBac_NPPRV1shRNA MOI 200 25 25 
rBac_NPPRV1shRNA MOI 300 25 25 
rBac_NPPRV1shRNA MOI 400 12.5 25 
   
Virus control 100 100 
rAd _NPPRV1shRNA MOI 100 75 100
rAd _NPPRV1shRNA MOI 200 75 100
rAd _NPPRV1shRNA MOI 300 75 100
rAd_NPPRV1shRNA MOI 400 75 100
        
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: Inhibition of PPRV N protein expression by rBac_NPPRV1shRNA measured by 
flow cytometry.  
 
 
2.3.4 siRNA NPPRV1 delivered by PepFect6 and PepFect14 inhibits nucleoprotein 
expression by PPRV    
PF6 is capable of efficiently transfecting siRNA at siRNA/PF6 molar ratio of 1/10. 
Transfection of siRNA NPPRV1 by PF6 at final concentration of 100 nM inhibits N gene 
expression by more than 99% while transfection of the irrelevant siRNA NRPV1 has no 
inhibitory effect (Fig. 28).  However, its efficiency declines when transfection is performed in 
the presence of increasing FBS percentages and no inhibitory effect of siRNA NPPRV1 is 
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found when transfection is performed in 100% of FBS (Fig. 29). PF14 is apparently less 
efficient in transfecting siRNAs compared to PF6 at siRNA/PF14 ratio of 1/10 (Fig. 30). 
However an increase in siRNA/PF14 ratio does increase the inhibitory effect of siRNA (Fig. 
31). Moreover, transfection of siRNA with PF14 appears to be less affected by presence FBS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: Inhibition of PPRV N protein expression by various siRNA NPPRV1 doses 
transfected by PF6, measured by flow cytometry.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: Inhibition of PPRV N protein expression by siRNA NPPRV1 transfected by PF6 
upon transfection in the absence or presence of various FBS percentages, measured by flow 
cytometry.  
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Figure 30: Inhibition of PPRV N protein expression by siRNA NPPRV1 transfected by PF14 
upon transfection in the absence or presence of various FBS percentages, measured by flow 
cytometry.  
 
 
 
 
 
 
Figure 31: Inhibition of PPRV N protein expression by siRNA NPPRV1 transfected by PF14 
in absence or presence of 30% FBS, measured by flow cytometry.  
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2.4 Discussion 
This study provides evidence that the recombinant adenovirus or baculovirus expressing 
active shRNAs can interfere with the replication of PPRV in vitro. However, the baculovirus 
proved to be more efficient than adenovirus vector when used at same MOIs. The low 
efficiency of the adenovirus against PPRV replication differs from other studies in which 
other pathogens were targeted. In vitro, shRNA-expressing adenoviruses achieved titer 
reductions of 3 log10 and 1.39 log10 for porcine picornavirus and circovirus when used at 
MOIs of 80 and 1000, respectively [225, 362]. Moreover, the results obtained in this study 
differ also from the results obtained previously by our group using the same recombinant 
adenovirus in the same conditions (see “State of the art” chapter of this document). The 
reason for this efficacy discrepancy is not really known. The initial experiments were 
performed with the rAd_NPPRV1shRNA vector which was produced at CIRAD while later in 
vitro as well as in vivo experiments were performed using the rAd_NPPRV1shRNA vector 
which was produced and purified by another laboratory (using bio-fermentor growth and 
purification by chromatography). The process may have modified the virus. Moreover it is 
known that many chromatographic elution buffers used for Adenovirus purification 
procedures are not suitable for in vivo manipulations [363]. Thus the two lots of 
rAd_NPPRV1shRNA were not the same and it could be at the origin of this discrepancy. 
Anyhow, it remains to be evaluated. Here, the rAd_NPPRV1shRNA did not reduce PPRV titers 
more than 0.7 log10 (Fig. 25) and higher concentrations of this vector showed to be deleterious 
to transduced cells.  Whereas, the rBac_NPPRV1shRNA tested in this study, when used at MOI 
of 400, could reduce PPRV replication by 2.19 log10 (Fig. 26b), which is higher than other 
comparable studies using baculoviral vector for delivery of shRNA against other viral 
pathogens in vitro. Lu et al., [332] using baculoviral vector expressing shRNA against 
nucleoprotein of porcine arterivirus, at MOI of 625, could inhibit viral titers up to 0.6 log10. 
While Suzuki et al., [335, 364], reported a decrease in titer for human influenza viruses to a 
maximum of 0.9 log10, after in vitro transduction with baculoviral vector expessing 
bifunctional shRNA at MOI of 100.  
 
Inhibition of PPRV titer and N viral protein expression by 2.1 log10 and 73%  respectively, by 
rBac_NPPRV1shRNA  is lower than the N protein inhibition by 90% and a reduction of PPRV 
progeny by 3-4  log10 that our group have obtained by siRNA NPPRV1 delivered by 
Lipofectamine 2000™  [350]. Moreover, highest inhibition of PPRV progeny titers was 
obtained 72h post-challenge for the higher challenge dose of PPRV (MOI 0.1) but the 
inhibitory effect tends to decline by 96h (Fig. 26b). This result is surprising since as far as 
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longevity of action is concerned shRNA expressing viral vectors normally have advantages 
over chemically synthesized siRNAs. It is reported that less than 1% of the introduced siRNA 
duplexes remain in the cell 48 hours after administration, whereas the shRNA can be 
continuously synthesized by the vector in the host cells, therefore, its effect should be much 
more durable [185]. However, as the viral vectors expressing shRNA used here are replication 
deficient, shRNA expression is limited and can get diluted over time due to continuous cell 
division, while the target virus may continue to replicate in non-transduced cells producing 
ever more mRNA and can also re-infect other cells. Maximum inhibition was observed 96 
hours post challenge, when the cells transduced cells with high baculovirus MOIs were 
challenged with the low PPRV challenge dose (MOI 0.01) (Fig. 26a). 
 
Anyhow, the in vivo application of this viral vector can be advantageous when compared to 
liposomes since baculoviruses do not have deleterious effects on mammalian cells even when 
used at very high concentrations [339]. Indeed, we did not find any adverse effects of 
rBac_NPPRV1shRNA in Vero cells even when used at an MOI of 400. On the other hand, 
baculoviruses seem to be susceptible to complement inactivation [336] that could make it 
impracticable to in vivo application. However, chemical or genetic modification, can 
overcome this problem [337, 338]. Furthermore, morbillivirus infections occasionally lead to 
infection of nervous system as well [16, 17], while the baculoviral vectors are not only 
capable of transducing nervous tissues in mouse upon being injected into brain but have also 
been reported  to cross blood brain barrier [340].  
 
Finally, two new chemical vectors, which are CPPs named the PF6 and PF14, were tested for 
their ability to transfect the siRNA NPPRV1 in Vero cells. The siRNA NPPRV1 has already 
been validated to be effective against PPRV at concentration of 100 nM when transfected 
with Lipofectamine 2000™ [350]. Transfection of siRNA NPPRV1 at 100 nM with PF6 
could silence viral protein expression by 99% (Fig. 28) which is higher than around 90% 
inhibition obtained with Lipofectamine 2000™ [350]. Interestingly, even at 50 nM, siRNA 
NPPRV1 transfected with PF6 could inhibit protein expression by 86.5% while it was only 
78% with Lipofectamine 2000™ [350]. Therefore, PF6 has a better efficacy compared to 
Lipofectamine 2000™.  
 
The PF14 is less efficient as reflected by a lower inhibition of N gene expression by PPRV 
(Fig. 30). However a higher siRNA/PF14 ratio of 1/15 had better effects, thus suggesting that 
a further increase of siRNA/PF14 ratio may improve antiviral activity (Fig. 31). Moreover, 
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PF14 is less affected in the presence of serum compared to PF6 (Fig. 31 and Fig. 29). 
However, at the siRNA/PF ratio of 1/10, the PF6 is still around 2.6 and 5.5 times more 
efficient, when transfection is performed in the presence of 30% and 60% of FBS, 
respectively. The inhibitory effect of higher concentration of serum in the PF6 and PF14 
activities remains to be evaluated.  
In conclusion, a recombinant replication deficient adenovirus and a baculovirus expressing 
shRNA against nucleoprotein of PPRV were constructed and tested in vitro. This study shows 
that both recombinants can inhibit PPRV replication in vitro. However, the baculoviral vector 
was more efficient. A CPP PF6 can deliver siRNA NPPRV1 effectively in vitro resulting in 
an almost complete inhibition of N gene expression by PPRV. PF14, although has a lower 
transfection efficiency in vitro, appears to be more serum resistant.   
 
The PF6 and rBac_NPPRV1shRNA vectors were efficient in vitro however whether these would 
prove equally efficient for inhibition of PPRV replication also in vivo needs to be elucidated. 
 
 
 
 
 
. 
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PART. 3: 
First contributions towards the development of a small animal model for 
the assessment of siRNA activity in vivo 
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3.1 Introduction 
Final potential beneficiaries of an antiviral therapy based on siRNA against morbilliviruses 
are large species like ruminants, dogs and possibly humans. However, the demonstration of in 
vivo efficacy can hardly be established directly in the target species for ethical, safety and 
economic reasons. Therefore, a small animal model is highly desirable to generate the proof 
of concept and also demonstrate the safety and efficacy of such an approach. Validated small 
animal models for morbillivirus infection are not frequent. This is probably due to a long 
virus-host co-evolution, limiting cross-species transmission. 
 
However, for measles virus, a mouse model for experimental challenge was developed 
recently [365]. Since we have identified active siRNA against this virus, the use of this model 
was initially considered. Nevertheless, for intellectual property reasons, this model could not 
be transferred to our laboratory. Another small animal model based on Marmosets could be 
used as these have been shown to be susceptible to measles [366, 367]. In addition, the model 
requires the manipulation of virulent measles virus strains. Although zoonotic diseases are 
currently investigated in our laboratory, we are not primarily in a human health research unit. 
The permission to use virulent measles virus strains is therefore a long and tricky process. A 
lapinized strain of rinderpest virus was shown to induce disease in rabbits [368]. However, the 
use of rinderpest virus strains is not recommended since this disease is about to be eradicated 
globally and the propagation of the virus in target or non target species always increases the 
risk for pathogen escape. In addition, the in vivo validation of siRNA against an eradicated 
disease would have a limited impact. 
 
For PPRV, the third virus for which we have demonstrated an in vitro activity of siRNA, no 
animal model is available. For this reason, we decided to launch a strategy for developing a 
mouse model for PPRV infection. Recently, mice that are knocked out for the interferon type 
I receptor (IFNAR-/-) were shown to be highly susceptible to bluetongue virus [369]. The 
research team that established this model was contacted and collaboration was initiated to test 
a virulent PPRV challenge on these IFNAR-/- mice. However, these mice never developed 
disease after PPRV challenge or sero-converted against the virus (data not shown). 
 
An alternative strategy was then designed to enable an in vivo assessment of systemic siRNA 
delivery for efficacious knock down of a morbillivirus gene.  
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3.2 Development of a non-infectious model to test in vivo the delivery of siRNA 
In a first approach, a non-infectious model was designed with the objective of generating 
kinetic and quantitative measurements of RNA interfering activity in a peripheral tissue. This 
model consisted of the expression of a luminescent Firefly reporter gene downstream of the 
target sequence of a siRNA directed against nucleoprotein gene of PPRV (named NPPRV1). 
The expression of this reporter gene is self-contained in the tibialis anterior (TA) muscle of 
mice after intramuscular injection of the plasmid containing the expression cassette driven by 
the human cytomegalovirus promoter (pCMV). For the kinetic and quantitative measurement 
of luminescence, we selected a method based on bioluminescence imaging (BLI) of mice 
allowing a measurement once a day over a week for all treated animals. Bioluminescence is a 
chemo-luminescence reaction only achievable by a living organism and produces light that 
can be imaged by non-invasive techniques. It has been used to monitor specific cellular or 
genetic activities in the animals. This system is therefore perfectly adapted to test different 
delivery systems for our siRNA, with a dynamic approach in live animals. In this method, a 
cooled charged couple detector (CCD) camera is used to quantify photons emitted from a 
light source localized in deep tissues. Generally, luminescence is preferred for that purpose 
because there is no such light emission in natural tissues and therefore the signal/noise ratio is 
very high. 
 
The most often used luminescence marker is the Firefly luciferase which cleaves the luciferin 
substrate and generates photons that are detected by the camera. We decided to use this 
reporter gene in our approach. However, the normalization of the signal required later on the 
use of a second “house-keeping” marker to minimize variability among mice. 
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3.2.1 Material and methods 
 
3.2.1.1 Production and in vitro validation of a siRNA-NPPR1-Firefly_luciferase-2 
reporter system 
The reporter system was constructed according to the strategy depicted in figure 32. Briefly, 
the Firefly luciferase-2 (luc2) gene was amplified from a commercial reporter plasmid 
pGL4.51[luc2/CMV/Neo] Vector (Promega) using PhusionTM High-Fidelity DNA polymerase 
(FINNZYMES, Finland) with the following primers: forward sequence 5’-GGA-TCA-ACT-
GGT-TTG-AGA-AAT-GGA-AGA-TGC-CAA-AAA-CAT-TAA-GAA-GGG-C-3’, reverse 
sequence 5’-TTA-CAC-GGC-GAT-CTT-GCC-GCC-CTT-C-3’. The forward primer 
consisted in the target sequence of the siRNA-NPPRV1 (in bold), followed by the 
complementary sequence of the Firefly luciferase-2 gene. This modified gene was then 
inserted into an expression plasmid vector (pCI-neo Mammalian Expression Vector, 
Promega) by blunt ended ligation. The expression capacity of this construction was then 
assessed in vitro by transfection of Vero cells with 100 ng of the plasmid and Lipofectamine™ 
2000 (Invitrogen), according to the manufacturer’s protocol. A positive control of expression 
consisted of the original commercial plasmid having the luc2 gene (pGL4.51, Promega). The 
luciferase gene expression was measured at 24-48 hours post-transfection by ONE-Glo™ 
Luciferase Assay System (Promega) with a luminometer (VictorII, Berthold-Wallac). Results 
were expressed as relative luminescent units (RLU). The down-regulation of the siRNA-
NPPRV1-Firefly luciferase-2 construction, later on named psiRNA-Fluc, by siRNA NPPRV1 
was then validated in vitro by co-transfection of both molecules in Vero cells with 
Lipofectamine™ 2000 (Invitrogen) 
 
3.2.1.2  In vivo validation of Firefly luciferase reporter systems 
In order to test the in vivo delivery of siRNA against the psiRNA-Fluc, a model consisting in 
a dynamic monitoring of the luciferase expression in mice by bioluminescence imaging (BLI) 
was developed. The siRNA-Fluc gene in pCIneo plasmid (psiRNA-Fluc) was appropriately 
diluted in PBS as indicated in the results section and injected under a volume of 60 µl in the 
TA muscle of mice as previously reported by others [370]. A positive control, consisting of 
the commercial Firefly luciferase gene under the same pCMV promoter (pGL4.51, Promega), 
was also used at the optimal dose of 10 µg/60 µl as previously defined (results not shown). 
 
Expression of the reporter gene was measured 48 hours after injection. Measurement was 
done between 8 to 15 minutes after two separate intra-peritoneal injections of 100 µl of D-
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Luciferin potassium salt (150 mg/kg, Caliper Life Sciences) using an IVIS-Lumina (Caliper 
Life Sciences). For imaging, anesthetized animals were placed in the light-tight chamber of 
the IVIS-Lumina. Photons emitted from luciferase-expressing plasmids were collected and 
integrated over three-minute periods. Pseudocolor images indicating photon counts were 
overlaid on photographs of the mice using the Living Image software version 4.0 (Caliper 
Life Sciences). Regions of interest (ROIs) were selected manually over the signal intensity. 
 
3.2.1.3  In vivo assessment of siRNA delivery against siRNA-Fluc 
Ten mice were split into two groups of five. One group received over three consecutive days, 
the siRNA-NPPRV1 at 40 µg/dose/mouse in a liposome-based emulsion (Aonys, Medesis 
Pharma, Montpellier) administrated by the intra-rectal route. This delivery system has been 
previously validated for siRNA delivery in mice targeting other genes (unpublished results). 
The second group of 5 mice received an irrelevant siRNA (MPPRV10) targeting the matrix 
protein of PPRV. Twenty four hours after the first administration of the siRNA-NPPRV1-
Aonys, all mice received in the left leg 10 µg/60 µl of pGL4.51 and 30 µg/60 µl of psiRNA-
Fluc (dose chosen after the previous in vivo test). All mice were imaged as previously 
described, 48 hours after plasmid injection (72 hours after first administration of the siRNA). 
 
3.2.1.4  Inclusion of a second reporter gene to normalize the in vivo psiRNA-Fluc 
The initial in vivo test of siRNA delivery showed that the signal intensity between mice was 
highly variable and thus required further normalization. The observed variability was ascribed 
to the lack of accuracy of pDNA injection/expression in the mouse TA muscle. It was decided 
to develop a protocol based on a co-injection of the Firefly luciferase reporter gene with 
another reporter gene retaining a stable expression over time. This stable reporter gene would 
then be considered as a sort of house-keeping gene and serve for normalization. 
 
The Renilla luciferase gene was selected as a second luminescent reporter gene. The enzyme 
expressed by this gene has a specific substrate that does not cross react with that of the Firefly 
luciferase gene. Conversely, the D-Luciferine is not used by Renilla. However, the emission 
spectra of the two substrates are overlapping, thus requiring a sequential injection of the 
substrates in mice. The plasmid vector pGL4.75[hRluc/CMV] expressing Renilla luciferase 
gene under the pCMV promoter was bought from a commercial company (Promega). After in 
vitro validation using the same approach than for the Firefly luciferase gene, the Renilla was 
probed in vivo. Three mice received in both tibialis muscles a co-injection of pGL4.51 
(Firefly luciferase, 10 µg) and pGL4.75[hRluc/CMV] Vector (Promega) (Renilla luciferase, 
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100 µg) in 60 µl of PBS. Seventy two hours later, the mice were imaged 4 minutes after 
intravenous injection of Coelenterazine h (the substrate of Renilla, 22 µg in 150 µl). Twenty 
minutes later, the mice were injected with D-Luciferin as previously described and again 
imaged. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: Schematic presentation of siRNA-NPPR1-Firefly luciferase-2 reporter gene 
“psiRNA-Fluc” construct. 
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target sequence 
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3.2.2 Results 
The psiRNA-Fluc construction was achieved and tested in vitro in comparison with the 
commercial Firefly luciferase gene (pGL4.51, Promega). Both constructions have an 
expression driven by the pCMV promoter. The luciferase expression by psiRNA-Fluc 
construction was first found to be around 20 times more than the expression of pGL4.51 
 (data not shown). In a second step, the psiRNA-Fluc was probed in presence of the siRNA-
NPPRV1 or an irrelevant siRNA in comparison with PGL4.51. The table 4 shows that 
siRNA-NPPRV1 specifically inhibited the expression of luciferase by psiRNA-Fluc and not 
by the original pGL4.51 Firefly reporter. In addition, the irrelevant siRNA could not down-
regulate any construction, thus illustrating that the sequence placed upstream of the Firefly 
luciferase reporter gene was efficaciously targeted by our siRNA. 
 
Table 4: In vitro inhibition of luciferase expression by psiRNA-Fluc after co-transfection 
with siRNA NPPRV1. 
 
 pGL4.51 
(100 ng) 
psiRNA-Fluc 
(100 ng) 
Negative 
control 
 24h 48h 24h 48h 24h 48h 
20 pmole siRNA NPPRV1 16924 3183 13672 2584 134 174 
20 pmole -siRNA IR* 26527 7440 634592 92659   
40 pmole siRNA NPPRV1 17954 6166 9592 2344   
40 pmole-siRNA IR 21335 3047 257299 72207   
*IR: irrelevant 
 
Before testing the delivery of siRNA NPPRV1 in vivo, we tried first to calibrate the amount 
of psiRNA-Fluc plasmid to be injected in the TA muscle. Forty eight hours post injection of 
the reporter plasmids, the mice were injected with D-Luciferin and imaged. Results are shown 
in figure 33. The reproducibility of the positive control was not perfect in this assay since the 
second mouse showed almost no signal. However, the dose/effect of psiRNA-Fluc was 
considered as acceptable. Since, the production of micrograms of plasmid is expensive and 
time-consuming, we considered from this trial that a dose of 30 µg/60 µl for psiRNA-Fluc 
would be satisfactory enough for the next studies although the signal at this dose may be 
lower than the one resulting from 10 µg/60 µl of pGL4.51 (see mouse 3 in Fig. 33). 
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(a) 
 
 
(b) 
 
 
Figure 33: Determination of the optimal dose for psiRNA-Fluc in vivo. (a) In the three mice, 
PGL4.51, considered as the positive control, was injected at a constant dose (10 µg/60 µl) in 
the left leg. As depicted from left to right, the psiRNA-Fluc was injected in the right leg at 3, 
10 and 30 µg/ 60 µl. (b) The histogram shows the total photons measured at each ROI per 
second and surface (p/s/cm²). 
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The RNA interference against our psiRNA-Fluc reporter system was tested using a liposome-
based formulation developed by a private company (Medesis Pharma, Montpellier). The 
delivery of siRNA with this system requires three consecutive deposits in contact with the 
rectal mucosa. Results are shown in Figure 34. For all mice, whatsoever the treatment 
received, luciferase expression increased from day 1 to day 2 after the plasmid injection. 
Afterwards, the increase became inconsistent. The expression of pGL4.51 was comparable 
between the group treated with the specific siRNA-NPPRV1 and the group treated with the 
irrelevant siRNA. A difference was observed between the two groups when considering the 
expression of psiRNA-Fluc. However, this difference was not significant because of a high 
heterogeneity within each group with some non–responding individuals (Fig. 34). This 
observation confirmed what was already observed in the previous test (Fig. 33). This 
variability resulted from the quality of plasmid injection and not from the substrate 
bioavailability after intraperitoneal injection as it persisted over days and after repeated 
substrate injections. Therefore, we decided to develop a double labeled system to assess the 
efficacy of plasmid injections and to normalize the test signals. 
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34: In vivo imagery of mice treated with siRNA-NPPRV1 (inside the green zone) or 
with an irrelevant siRNA. All mice were injected in the right and left legs with psiRNA-Fluc 
(30 µg/60 µl) and pGL4.51 (10 µg/60 µl), respectively. They were imaged at different time 
points after plasmid injections. The picture (a) shows the results at day 3 post-injection and 
the histogram (b) shows average total photons (p/s/cm²) measured in each group for the two 
siRNAs administered at different days after plasmid injection. 
p/s/cm2 
Days
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For the normalization of the signals, we selected a second bioluminescent marker. Although, 
it is possible to use a fluorescent marker in the IVIS-Lumina bioimaging system, in our hands, 
fluorescence signals were hardly detected from the TA muscle compared to the Firefly 
luciferase-2 gene (data not shown). The Renilla reporter gene was therefore evaluated. Three 
mice were co-injected with the two reporter genes in both legs and sequentially imaged, first 
after IV injection of Coelenterazine h and then after IP injection with D-Luciferin. Results are 
shown in Figure 35. Renilla luciferase was found to be 1.5 to 2 log10 less bright than Firefly 
luciferase-2, which is an expected result since the former is known to give less signal. For 
both signals, we could reproduce the variable success of intramuscular injections of the 
plasmid vectors. However, the dot plot shows a good correlation between the two markers. In 
conclusion to this trial, it appears that the results obtained from both legs of mouse 1, the left 
leg of mouse 2 and the right leg of mouse 3 could be exploited in a siRNA in vivo assay since 
normalization can be envisaged. 
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
Figure 35: In vivo measurement of the co-expression of Renilla and Firefly luciferase genes.  
(a) Top picture shows Renilla activity, 4 minutes after IV injection of Coelenterazine h and on 
bottom picture the Firefly luciferase-2 activity, 10 minutes after IP injection of D-Luciferin. 
(b) The dot plot illustrates the correlation between the two signals. 
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GENERAL DISCUSSION 
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The viruses belonging to the Morbillivirus genus cause devastating diseases affecting humans, 
marine mammals, domestic and wild canines, small ruminants and large ruminants. They are 
emerging or re-emerging pathogens because of their high contagiosity and the difficulty to 
achieve a high enough immunity cover to prevent the appearance of epidemics. In spite of the 
availability of an effective vaccine, more than 30 million cases of acute measles with 
approximately 345,000 cases of infant deaths are annually reported [42]. For the control of 
measles, 95% of the population should ideally be vaccinated to avoid any new outbreak. But 
this objective is extremely difficult to achieve, even in Europe, because a small proportion of 
children is still not vaccinated or do not develop a sufficient immunity. Although effective 
vaccines against canine distemper are also available, a resurgence of the disease has been 
reported even in vaccinated dogs [49, 50]. After massive international efforts, rinderpest has 
been eradicated worldwide and the world will be declared rinderpest free by 2011 [38]. 
Eradication of rinderpest has brought PPR to the limelight, highlighting the need for its 
control. Although an efficacious vaccine is available and the fact that the disease hits the 
economically most vulnerable sections of world population [65], there is no international 
program for eradication of PPR. 
 
The need for antiviral treatments concerns more particularly the diseases for which there are 
no efficacious vaccines. However, it is now possible to foresee antiviral drugs as an 
alternative or a complementary line of defence against infections. Thus, an RNAi based 
antiviral therapy against PPR may prove economically useful for control of epidemics not 
only if used alone but also along with vaccination.  The vaccination against PPR is actually 
resorted to as an emergency measure in case of an epidemic. However, only the healthy 
animals can be vaccinated and it takes around a week for the development of the protection. 
In case of a PPR outbreak, use of an effective antiviral therapy along with ring vaccination in 
and around the disease pockets could help not only to control the epidemic but also to prevent 
extensive economic losses.  
 
In a recent past, there has been a spectacular expansion of the comprehension of the molecular 
mechanisms of the viral cycles. Further, the efforts to contain the sudden rise of HIV have 
lead to the development of numerous antiviral molecules whose number has increased tenfold 
over the last ten years. Strategies developed to counter viral diseases have identified new 
molecular targets. Interfering RNA constitute an interesting trail to follow because of the in 
vitro selective degradation of the viral RNA renders them highly specific and effective in their 
action. However, even after more than a decade after its discovery, RNAi therapeutics are still 
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hampered by the challenge of in vivo delivery. Although siRNAs have been successfully 
delivered locally, for instance for treatment of age-related macular degeneration (AMD) 
[371], systemic delivery has proven more difficult. Majority of the current clinical trials for 
siRNA based therapies are for local administration while relatively few systemic delivery 
systems have entered clinical trials and almost all are still in Phase-I (Tab. 5) [372]. In this 
context, since PPR is an acute systemic infection, it is an extremely valuable model for 
systemic siRNA delivery with implications for treatment of measles in humans. 
 
Table 5: Current development stage for siRNA therapeutics (according to Sliva and 
Schnierle., 2010) [373]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The silencing capacity of the siRNA developed in CIRAD was achieved in vitro using 
delivery systems like liposomes and adenovirus. In the course of this study, the in-vivo phase 
was foreseen using the non viral in comparison to the viral vector systems. However for 
delivery of large quantities of siRNAs in the target species of PPRV commercialised chemical 
vectors are extremely expensive. . A in-house cationic lipid based formulation was therefore 
developed and used for in vivo delivery of siRNA NPPRV1. Replication deficient adenoviral 
human type 5 (Ad5) vectors are commonly used in siRNA based genetic therapy because they 
do not have the ethical problem associated to insertional mutagenesis which precludes the use 
of the retroviruses. In addition, during the time of this work, a study reported the successful 
therapeutic effect of adenoviruses expressing shRNA in vivo against foot and mouth disease 
virus (FMDV) infection in guinea pigs and swine [23, 362]. This led us to use our Ad5 vector 
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rAd_NPPRV1shRNA for in vivo delivery of shRNA NPPRV1. Although the incidence of oculo-
nasal discharges and stomatitis appeared to be reduced for animals treated with liposomes, the 
diarrhoea and pyrexia were in contrast increased and in any case, the differences were 
statistically significant. One of the possible reasons for this, was the insufficient relative 
siRNA/lipids concentration administrated to the animals resulting from the necessity to 
achieve acceptable injectable doses. Indeed, the use of diluted siRNA and lipid solutions for 
complex formation as were used for in vitro study, would have resulted in large volumes for 
intravenous injection which would not be feasible for injecting goats. However, while trying 
to use more concentrated siRNA and liposome solutions for achieving final injectable doses, a 
problem of precipitation occurred. Then, the siRNA/lipids ratio of had to be reduced by three 
for complex formation to avoid precipitation. This siRNA/lipids ratio tested in vivo was later 
on tested in vitro and was found to be less efficacious in PPRV CPE inhibition in vitro.  
 
The lack of adenovirus effect in vivo could probably be due to differences in the tropism of 
the two viruses. While morbilliviruses, are primarily lymphotropic and secondarily 
epitheliotropic [61, 124, 132], lymphatic tissues are not transduced efficiently by adenovirus 
type 5 vectors [354] and are not correctly transfected by liposomes as well [374]. Whether the 
in vivo transfection or transduction of the epithelial tissues alone, with insufficient 
transfection/transduction of lymphatic tissues, can suffice for having a therapeutic effect 
cannot be confirmed. Similarly, Chen et al., could protect swine from a major clinical disease 
through adenoviral vectors targeting FMDV, however they incriminated the different tissue 
distribution of rAd5 and FMDV as responsible for the limited inhibition of FMDV infection 
in vivo [23]. For effective delivery of siRNA/shRNA against PPRV, the 
transfection/transduction of lymphatic tissues is desirable for improved therapeutic effect. As 
perspectives, ligands targeting lymphocytes, could be attached to metabolically biotinylated 
adenoviral [375], baculoviral vectors, liposomes and CPPs for improving 
transduction/transfection of the target tissues. These modified viral and chemical vectors 
could be tested in vitro on goat PBMCs. However for initial screening of unmodified vectors 
in vitro, the Vero cells remain ideal as they lack genes for interferon (IFN), while if 
lymphocytes or other cell lines are used the effects of IFN may over shadow the contribution 
of RNAi upon PPRV replication [376-378]. RNAi experiments in goats create several 
practical difficulties. In our in vivo experiment, we could not test several doses for adenoviral 
vector in vivo as it would have required large number of goats; therefore in future in vivo dose 
optimization is still needed. The results of Chen et al., indicated that all three swine receiving 
a low adenoviral dose (4 X 109 PFU) were completely protected against FMDV challenge. 
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However, the antiviral effect was somewhat impaired in the animals treated with a high dose 
of adenoviruses (8 X 109 PFU) whereby only one animal was protected [23]. They suggested 
that this may have been due to inhibitory effect of adenoviral VA1 non-coding RNA, which 
they think should be removed in future for more efficient delivery [23].  
 
Since the first attempt at in vivo delivery of siRNA did not give the expected results, it 
entailed us to search for more efficient viral or non-viral vectors which could be possibly used 
for future siRNA/shRNA delivery in vivo. For this purpose, recombinant adenovirus and 
baculovirus vectors expressing short hairpin RNA (shRNA) against the PPR virus (PPRV) 
were prepared and compared for efficiency in vitro. We found a lower efficiency of the 
adenovirus against PPRV replication compared to previous studies in which other pathogens 
were targeted [362]. In contrast, the recombinant baculovirus tested in this study proved to be 
more efficient than adenovirus vector when used at same MOIs. A reduction of 2.19 log10 on 
PPRV replication was observed  which is more than 1 log10 higher than other comparable 
studies involving baculoviral vectors [335, 364]. However, the reduction of NPPRV protein 
expression by 73% and PPRV progeny titre by 2.19 log10 with rBac_NPPRV1shRNA was lower 
than the one previously observed by our group when the siRNA were delivered to cell 
cultures by Lipofectamine 2000™. The latter reduced the PPRV nucleoprotein expression by 
90% and progeny titre by 3-4 log10 [350]. Although recombinant baculoviruses are easier and 
cheaper to produce in high quantities than liposomes and do not have deleterious effects up on 
mammalian cells even at very high MOIs [339], they are susceptible to complement 
inactivation [336]. Chemical or genetic modifications, however, has been reported to be able 
to overcome this problem [337, 338]. In addition to baculovirus, we also investigated two new 
peptides (CPPs) named PF6 and PF14 for siRNA delivery. Transfection of siRNA NPPRV1 
with PF6 at 100 nM resulted in the silencing of viral protein expression by up to 99% which 
was higher than the inhibition achieved with Lipofectamine 2000™ (90%, [350]). In contrast, 
the PF14 was less efficient for the transfection of siRNA NPPRV1. Transfection could be 
improved by using higher siRNA/PF14 ratio but still it never reached efficacy of PF6. 
Unfortunately, the availability of PF14 was limited and we could not increase the ratio 
siRNA/PF14 as required. This was a pity since our results tended to show that PF14 was less 
prone to the negative effect of the presence of serum in the environment of the cells where 
had to be delivered the siRNA. In provisional conclusion, we could not discriminate clearly 
the suitability of two CPPs for future studies in vivo. This will require new in vitro trials or to 
test the two CPPs in vivo with the recombinant baculovirus. However, such an in vivo test is 
not feasible in the target species since it requires many large animals and large quantity of 
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expensive siRNA. Therefore, development of a small animal model to assess the in vivo 
performance of different delivery systems became an absolute necessity in the course of this 
work.   
 
To decrease the technical leap between the in vitro and in vivo evaluation and also improve 
the ethical, bio-security and economic aspects of the in vivo experiments the mouse model 
was investigated. From a technical point of view, a BALB/c mouse is more than 1000 times 
smaller than a goat and thus requires much lower quantities of siRNAs and vectors for 
experiments. Furthermore, the RNAi experiments with virulent PPRV require high 
containment animal facilities which are not available at CIRAD. Although PPRV infection of 
mice could be possible at the high containment laboratory of CIRAD, normal mice are 
resistant to PPRV infection. We tried to identify a susceptible mouse that could be infected by 
PRRV. IFN knockout mice were tested because they were recently shown to be highly 
susceptible to another ruminant virus, an orbivirus responsible of bluetongue disease [379]. 
However, PPRV challenge on these mice was unsuccessful since neither clinical signs nor 
viremia was detected. This failure is probably due to inability of PPRV to use mouse SLAM 
or CD150 receptors. To continue in this direction, the production of transgenic mice 
expressing sheep SLAM receptor will be required. Such a model was successfully developed 
for measles virus [380]. In the absence of a model for PPRV, a non-infectious strategy was 
developed instead to enable in vivo assessment of siRNA delivery. For this purpose, a 
luciferase expressing reporter plasmid having siRNA NPPRV1 target sequence was 
developed. Aim was to inject this construct into the mouse muscle and deliver siRNA via 
various vectors and measure effect of siRNA on luciferase expression by CDD camera. The 
siRNA NPPRV1 could knock down luciferase expression by psiRNA-Fluc in vitro, thus 
illustrating that the siRNA target sequence placed upstream of the Firefly luciferase 2 reporter 
gene was efficaciously targeted by our siRNA. The amount of psiRNA-Fluc required for 
injection into the mouse tibialis anterior (TA) muscle was determined for best in vivo imagery 
by CDD camera. Next, a liposome-based formulation developed by a private company was 
tested against our psiRNA-Fluc reporter system. However, luciferase expression was found to 
be inconsistent between legs and mice with some non-responding individuals. The variability 
was assumed to arise from the plasmid injection and not from the substrate bioavailability 
after intraperitoneal injection (performed in two steps at different sites to avoid possible 
failures of intraperitoneal injections). Owing to this variability, the difference observed 
between the treatment and control groups, considering the expression of psiRNA-Fluc, was 
not significant.  In order to manage this variability, a double labeled system was introduced, 
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using Renilla luciferase as a second house-keeping bioluminescent reporter to check the 
quality of plasmid injections and to normalize the results of siRNA activity. For both signals, 
the variability in accuracy of intramuscular injection of plasmid vectors was observed, 
however, a good correlation was obtained between the two markers, thus allowing 
normalization. Since normalization could be achieved, it appears that this mouse model can 
now be used for testing of siRNA delivery in vivo. Use of this bioluminescent reporter based 
mouse model would allow us to test not only the various siRNA or shRNA expressing viral 
vector doses but also would enable us to test other parameters like vector toxicity. The ethical 
aspects are also considered in this model since the mice are not infected but only receive 
reporter plasmids by the intramuscular route followed by daily injections of luminescent 
substrates, either intravenously or intraperitoneally. All administrations are practiced under 
gas anesthesia. Therefore, the animals suffer less as compared to a PPRV infection in small 
ruminants. 
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CONSCLUSION AND PERSPECTIVES 
 
A recombinant replication deficient adenovirus and a baculovirus expressing shRNA against 
nucleoprotein of PPRV were tested in vitro. This study showed that both recombinants can 
inhibit PPRV replication in vitro. However, the baculoviral vector was found to be more 
efficient. A CPP PF6 can deliver siRNA NPPRV1 effectively in vitro resulting in an almost 
complete inhibition of N gene expression by PPRV. Although PF14 has a lower transfection 
efficiency in vitro at the siRNA/PF14 ratio of 1/15, use of higher ratios may improve 
transfection. Furthermore, it is relatively serum resistant compared to PF6. Whether these 
vectors which have been found to be efficient in vitro, would equally be effective in siRNA 
delivery in vivo for inhibition of PPRV replication, needs to be elucidated. 
 
Since the systemic delivery of siRNA is the key issue for future therapeutic application, we 
have investigated a strategy based on the use of a non-infectious mouse model and a dynamic 
follow up of siRNA treatment by live imaging. We show in this work that it is possible to 
measure and standardize the expression of a bioluminescent reporter gene and thus, to 
quantify a down-regulation of such gene. The work is on-going to calibrate this experiment 
and then siRNA delivery will be tested again circumventing the initial problems of variability 
that result from inconsistent plasmid injections. This model will be very useful for comparing 
various vectors for systemic delivery of siRNAs. At the moment, in addition to the Aonys 
system by Medesis Pharma, our recombinant baculovirus and the CPP PF6 or PF14, described 
in the part 2, are promising candidates. 
 
Once the best candidates will have been identified in this non infectious model, the objective 
will be to confirm our observation in an infectious mouse model. Since mice are naturally 
resistant to PPRV, our approach will be based on the generation of a transgenic mouse 
expressing the sheep SLAM receptor for PPRV and being deficient for interferon type I 
responses (double knock-out mouse for interferon type I receptor: IFNAR-/-). A similar 
model (e.g. IFNAR-/- mice expressing human SLAM receptor for the measles virus) was 
developed for measles virus [365]. The idea is to adapt this model to PPRV. Once established, 
we will be able to test the RNA interference in mice in vivo: the inhibitory effect of siRNA 
will be measured in terms of reduction of clinical signs or mortality. In addition, the 
laboratory is also developing a bioluminescent PPR virus by reverse genetics. The final goal 
will be to test the control of PPRV replication by siRNA through bioluminescence imagery. 
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